Body · Sources

Type 2 diabetes

Also called type 2 · T2D · prediabetes · A1C · HbA1c · diabetes reversal · metformin · GLP-1 diabetes

Named sources. May contain inaccuracies or be incomplete. Not medical, legal, financial, or other professional advice.

Type 2 diabetes develops when the body responds poorly to insulin and the pancreas cannot supply enough to keep blood glucose in range. Blood tests establish diabetes; the clinical history helps establish its type. Prediabetes offers an opportunity to reduce or delay future diabetes. After diagnosis, useful care combines glucose management with protection for the heart, kidneys, eyes and feet. Some people achieve remission with supervised treatment, but remission still needs follow-up.

What type 2 diabetes means

Understanding how insulin and glucose work helps you distinguish a question about diagnosis from one about prevention or treatment.

Get the right tests when a number or symptom raises a question

Perhaps a routine blood test came back high, or thirst, frequent urination or blurred vision has made you wonder about diabetes. Glucose is sugar circulating in the blood; insulin is a hormone made by the pancreas that helps the body use and manage it. NIDDK explains that type 2 diabetes combines insulin resistance, meaning cells respond less well to insulin, with an insulin supply that cannot meet the body's needs. Symptoms may develop slowly or be absent. A clinician uses laboratory tests and the history to establish the diagnosis and distinguish type 2 from other forms, including adult-onset type 1. Bring the actual result rather than trying to settle the question with an online symptom list.

Symptoms & Causes of Diabetes 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

Use a prediabetes result as a reason to discuss prevention

If you were told that your glucose is 'borderline,' ask which test and range that describes. Prediabetes means glucose is above the usual range but below the diabetes threshold; it signals increased future risk, rather than an inevitable next stage. William Knowler and the Diabetes Prevention Program researchers tested supported lifestyle change and metformin in adults already at high risk and found that both reduced new diabetes during the trial. That finding gives a reason to ask about a structured prevention service. It does not mean everyone with a mildly elevated A1C has the same risk or needs the same treatment. The useful question is what your result, other risks and available support mean together.

Diabetes Tests & Diagnosis Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

Build a care plan around the goals that matter to you

A new diagnosis can sound like a demand to change everything at once. The ADA's 2026 Standards instead organize care around individual glucose and weight goals, other health conditions, safety, preferences and access. Eating patterns, movement, medicines and follow-up each have a role; a diabetes educator or registered dietitian can help turn the plan into something usable. Two people with the same A1C may need different medicines because one also has heart failure or kidney disease. Ask what each part is intended to accomplish and which problem deserves attention first. Trouble paying for a medicine or fitting meals around shifts is information the care team needs to make the plan work.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Healthy Living with Diabetes The Price of Insulin: A Q&A with Kasia Lipska

Keep routine screening and immediate safety in the same plan

Feeling well after diagnosis is welcome, but it cannot tell you whether every organ is protected. NIDDK explains that early kidney and retinal damage can be silent, while nerve damage can make a foot injury difficult to feel. These are reasons for scheduled checks, not predictions that you will develop every complication. Treatment adds another question: insulin and some insulin-releasing medicines can cause hypoglycemia, meaning blood glucose drops too low. The plan therefore needs both long-term screening and clear instructions for recognizing and responding to a low. Ask when your eyes, kidneys and feet will be checked and whether your medicines require a low-glucose response plan.

Diabetic Kidney Disease Diabetic Eye Disease Diabetes & Foot Problems Low Blood Glucose (Hypoglycemia)

How to read A1C and glucose results

Keep the test name, units and timing beside the number

A1C, also called HbA1c, measures glucose attached to hemoglobin in red blood cells and reflects roughly the preceding three months, with more influence from recent glucose levels. It is reported as a percentage and does not require fasting. Fasting plasma glucose is a laboratory snapshot after at least eight hours without calories. An oral glucose-tolerance test measures the response two hours after a standardized glucose drink. These tests examine different aspects of glucose regulation, so they do not always agree. NIDDK and the ADA distinguish diagnosis from home monitoring: a meter reading can be useful in an established care plan, but an over-the-counter meter or sensor does not complete the diagnostic process.

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 Diabetes Tests & Diagnosis

Use diagnostic thresholds as questions for your clinician

For nonpregnant adults, ADA diagnostic criteria include A1C of at least 6.5%, fasting plasma glucose of at least 126 mg/dL (7.0 mmol/L), or two-hour plasma glucose of at least 200 mg/dL (11.1 mmol/L) during a 75-gram glucose-tolerance test. Random plasma glucose of at least 200 mg/dL with classic high-glucose symptoms or a hyperglycemic crisis is another route. U.S. prediabetes ranges include A1C 5.7–6.4%, fasting glucose 100–125 mg/dL and two-hour glucose 140–199 mg/dL. Those are diagnostic categories, not a personal treatment target. Pregnancy uses a separate assessment pathway. Save the report so a clinician can interpret the correct test rather than a number remembered without its context.

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 Diabetes Tests & Diagnosis

Resolve confirmation and conflicting results before drawing conclusions

The ADA requires confirmation when the presentation is not unequivocal: two abnormal results may come from different tests collected together or from testing at different times. A repeat visit is therefore not always necessary, and one normal test does not automatically cancel another repeatedly abnormal test. If A1C and measured glucose disagree, the team should investigate the reason. Pregnancy, some hemoglobin variants, anemia and conditions affecting red blood cell turnover can make A1C misleading; plasma-glucose criteria may be needed. Ask which result establishes the diagnosis, whether confirmation is complete and how the type was determined. Age or body size alone should not decide that every adult has type 2 diabetes.

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

What the major studies actually found

Prevention, remission, glucose control and fewer cardiovascular events are different outcomes. Each study answers its own question.

Supported prevention reduced new diabetes in high-risk adults

Knowler and the DPP Research Group randomized 3,234 adults without diabetes but with elevated fasting glucose and high glucose after a standardized glucose drink to intensive lifestyle support, metformin or placebo. The lifestyle program included coaching and trial goals of at least 7% weight loss and 150 minutes of activity each week; these describe the intervention, not a personal prescription. Over an average 2.8 years, diabetes incidence was 4.8, 7.8 and 11.0 cases per 100 person-years in the lifestyle, metformin and placebo groups. A person-year is one person's year of observation. The familiar 58% and 31% reductions are relative reductions in incidence versus placebo, not percentage points subtracted from everyone's risk. The result supports organized prevention, with follow-up and support, rather than a detox or an unsupported promise to try harder.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin Diabetes Prevention Program (DPP)

More diabetes-free time is a meaningful prevention outcome

The 2025 DPP follow-up analyzed 3,195 original participants across a period extending to 21 years. Compared with original placebo assignment, mean diabetes-free survival was approximately two years longer with lifestyle assignment and 1.2 years longer with metformin; median differences were 3.5 and 2.5 years. Mean and median summarize the data differently and should not be interchanged. Individual observation periods varied considerably, and all groups were offered lifestyle sessions after the original trial, so this was not twenty-one years of unchanged, separate treatments. Much of the long-term separation came from early benefit. Read the finding as evidence that prevention can delay diabetes and reduce cumulative incidence, even though many people eventually develop it.

Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial

Glucose control protects small vessels while treatment safety still matters

UKPDS 33 randomized 3,867 adults with newly diagnosed type 2 diabetes to intensive glucose treatment with insulin or a sulfonylurea, an insulin-releasing medicine, or a conventional policy. Over about ten years, intensive treatment reduced microvascular endpoints by 25% relative to conventional treatment, including eye disease requiring retinal treatment. Microvascular means involving small blood vessels; this evidence is different from proving fewer heart attacks or strokes. Intensive treatment also produced more hypoglycemia and weight gain. Rury Holman's UKPDS work helps explain why sustained glucose management matters, but the study used an earlier treatment era. Its practical lesson is to pursue glucose control with attention to adverse effects, while managing blood pressure, cholesterol and organ risks alongside it.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Approach to Managing CKD in Diabetes

Supervised weight management achieved remission in a selected group

Michael Lean, Roy Taylor and colleagues conducted DiRECT across 49 primary-care practices in Scotland and England. Participants were aged 20–65, had diabetes for less than six years, had BMI 27–45 and were not using insulin. The intervention combined temporary formula-diet replacement, gradual food reintroduction, maintenance support and supervised changes to diabetes and blood-pressure medicines. At one year, 46% of the intervention group and 4% of controls met the trial's remission definition: A1C below 6.5% after at least two months off diabetes medicines. That is a substantial result for that program and population. It does not establish that an unsupervised restrictive diet, a juice cleanse or any one supplement reproduces the benefit or is safe.

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Remission includes monitoring and help with maintenance

The later international consensus led by Matthew Riddle uses remission for A1C below 6.5% measured at least three months after stopping glucose-lowering medicines. This differs from DiRECT's original two-month trial criterion. A good A1C while taking treatment can be excellent control without meeting that definition; stopping a beneficial medicine just to obtain a label is not a goal for this reading companion. Glucose can rise again, and ongoing observation and complication screening remain important. The University of Glasgow's report of the five-year DiRECT extension describes sustained remission in some participants and substantial difficulty maintaining weight loss. The extension followed a remaining subgroup and cannot be read as a repeat of the original randomized one-year result. Remission is a possible clinical outcome, not a promise of a permanent cure.

Consensus report: definition and interpretation of remission in type 2 diabetes Diet intervention links longer remissions of type 2 diabetes and improved health

Value lifestyle benefits and check heart-event evidence separately

Look AHEAD randomized 5,145 adults with overweight or obesity and type 2 diabetes to intensive lifestyle treatment or diabetes support and education. After a median 9.6 years, the intensive group had lost more weight and had better early A1C and fitness measures, but the primary cardiovascular outcome was not significantly reduced. Event rates were 1.83 versus 1.92 per 100 person-years; the hazard ratio was 0.95, with a confidence interval of 0.83–1.09. That interval includes no difference. The trial measured cardiovascular death, nonfatal heart attack or stroke, or hospitalization for angina. It neither makes lifestyle pointless nor proves that every activity program has the same result. It shows why care should retain lifestyle benefits and use direct outcome evidence for claims about heart protection.

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

Read a medicine's benefit by the event and population studied

A lower A1C, fewer heart-failure admissions and slower kidney decline are separate outcomes. The ADA's 2026 Standards recommend agents with demonstrated benefit for relevant heart and kidney conditions, sometimes irrespective of A1C. SGLT2 inhibitors reduce glucose reabsorption in the kidney; GLP-1 receptor agonists act on a hormone pathway involved in insulin release, appetite and digestion. These class names describe how drugs work, not identical evidence for every member. For heart failure, kidney disease or atherosclerotic disease, meaning disease involving plaque buildup in arteries, the specific drug, population and measured event matter. Ask which benefit supports the proposed medicine and how it will be monitored. Weight loss or a striking glucose response alone cannot establish that every product also prevents every cardiovascular or kidney outcome.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Approach to Managing CKD in Diabetes

Make daily care understandable and usable

Choose eating support that fits your life and your treatment

Carbohydrate includes sugars, starches and fiber, and it influences glucose after meals. That does not make every carbohydrate-containing food interchangeable or establish a single correct diet. Alison Evert and the ADA nutrition consensus authors describe individualized eating patterns rather than one ideal carbohydrate, fat and protein ratio. Food quality, quantity, culture, preferences, affordability and the ability to maintain the pattern all matter. Medical nutrition therapy means individualized assessment and counseling from a registered dietitian; it is more than handing someone a forbidden-food list. Discuss major changes, particularly fasting or sharply reducing carbohydrate, before making them when medicines can cause lows. The useful goal is an eating plan the care team can help you understand and safely sustain.

Imagine a person whose meal plan assumes a lunch break at noon, while their shift sometimes delays the break. They tell the dietitian what food is actually available and the prescribing clinician when meals are missed or delayed. The useful question is how the eating arrangement and treatment can work together safely, rather than which food to blame for every difficult reading.

At follow-up, they can report whether the agreed arrangement was possible and what still prevented it. If access to food or breaks remains unreliable, that is part of the care problem, not evidence that the person needs a stricter list. This invented situation does not specify a meal or medicine change. It demonstrates why cultural fit, affordability, work conditions and medicines belong in one individualized discussion, especially when treatment can cause low glucose.

Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Healthy Living with Diabetes

Make movement part of care with an appropriate safety plan

NIDDK describes regular activity as helpful for glucose, fitness, blood pressure and well-being. For someone who sits for much of a shift, the first practical issue may be finding a feasible activity rather than copying an athlete's routine. Existing foot problems, heart symptoms, functional limitations or medicines that cause lows may change what is appropriate and what monitoring is needed. Ask the care team how movement fits your health and treatment, and seek support for barriers. Ordinary food and movement habits are also discussed in STUDself; the related Learn topics on fitness, nutrition and sleep offer further named-source teaching. Those connections complement diabetes care rather than deciding a treatment plan.

Healthy Living with Diabetes Low Blood Glucose (Hypoglycemia)Diabetes & Foot Problems

Know why each medicine is in the plan

The 2026 ADA Standards make effectiveness, heart and kidney conditions, weight, hypoglycemia, tolerability, cost and preferences part of medication choice. Metformin remains useful for many people and may be chosen for effectiveness, affordability and tolerance. An SGLT2 inhibitor or GLP-1 medicine may be considered for a different or additional goal, and insulin can be appropriate when insulin supply is insufficient or glucose is severely elevated. Ask what benefit is expected, which adverse effects to report and when the plan will be reviewed. Different choices can both be reasonable. Raise supply or cost problems promptly rather than quietly rationing a treatment; Kasia Lipska's public insulin-cost work shows why affordability belongs inside the clinical conversation.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 The Price of Insulin: A Q&A with Kasia Lipska

Use screening results to protect organs before symptoms appear

Kidney checks combine urine albumin, a protein that may leak when kidneys are damaged, with a blood test estimating filtration, often called eGFR. They answer different questions and are not replaced by a normal A1C. NIDDK recommends yearly kidney testing for people with type 2 diabetes. A retinal examination checks the back of the eye for changes that clear everyday vision can miss. A foot assessment checks skin, circulation and sensation, since reduced feeling can hide a blister or wound. Keep the results and next review dates together, and have your clinicians set the appropriate eye and foot schedule. New wounds, sudden vision changes or other new symptoms deserve attention between routine appointments.

Diabetic Kidney Disease Diabetic Eye Disease Diabetes & Foot Problems

Keep a short record of the pattern and the barriers

A useful follow-up record contains the latest lab report, home readings if your team asked you to collect them, symptoms, medicine changes and questions about access or daily routines. Record the test's units and timing; otherwise a fasting result and an after-meal reading can look like conflicting answers to the same question. Note missed meals, unexpected lows or side effects without treating the record as a character score. Monica Peek's diabetes work emphasizes informed shared decisions, and the Behavioral Diabetes Institute identifies practical and emotional barriers as part of care. Bring one obstacle you want help solving. A record is useful when it improves the conversation, not when it creates an exhausting obligation to track everything.

Diabetes Tests & Diagnosis 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Monica Peek, MD, MPH — UChicago Medicine Healthcare Professionals Resources — Behavioral Diabetes Institute

Where treatment choices and evidence differ

These are real questions about fit, outcomes and durability. They do not turn every option into equally strong evidence.

Discuss treatment sequence in light of heart, kidney and access needs

The older 'metformin first for everyone' shorthand conflicts with a more condition-specific approach. The ADA/EASD consensus and 2026 ADA Standards give therapies with demonstrated organ benefits a role that need not wait for metformin to fail in people with relevant heart or kidney disease. Metformin may still be a sensible starting choice when those indications are absent and it fits the person's circumstances. The practical debate concerns sequence, combination, cost, adverse effects and priorities; it is not a contest between being pro-medicine or pro-lifestyle. A history of stroke, heart failure and chronic kidney disease are also distinct clinical problems, not one interchangeable indication for every newer drug. Ask which condition is driving the choice.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Compare eating patterns by sustained benefit and safety

Clinicians and researchers differ over how much to emphasize carbohydrate reduction versus other ways to improve diet quality and achieve weight goals. The ADA/EASD consensus reports short-term glucose benefits from lower-carbohydrate approaches, while noting that their comparative advantage is less evident with longer follow-up. It also recognizes Mediterranean and other individualized patterns. This is a disagreement about the best sustainable route for particular people, not evidence that one named diet is mandatory or that carbohydrate has no effect on glucose. Definitions of 'low carbohydrate' also differ across studies. Compare duration, actual adherence, medicine changes and outcomes before borrowing a headline, and discuss low-glucose safety when changing eating patterns.

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report

Match glucose targets to benefit, burden and the person

UKPDS supports long-term glucose management in newly diagnosed adults. ACCORD asked a different question in 10,251 generally older adults with established cardiovascular disease or additional cardiovascular risks: would an intensive strategy targeting A1C below 6.0% reduce major cardiovascular events compared with a standard strategy? The intensive arm was stopped after about 3.5 years because mortality was higher; severe hypoglycemia and major weight gain were also more frequent. That does not identify the harmful mechanism or prove that naturally having a low A1C is dangerous. It challenges the assumption that rapidly pursuing a near-normal number with an intensive treatment strategy helps everyone. The clinician and patient weigh the target, treatment burden and safety together.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Effects of intensive glucose lowering in type 2 diabetes 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

Evaluate remission approaches with eligibility and maintenance attached

The possibility of remission is established; how to make it accessible and durable for different people remains an active clinical question. DiRECT studied a particular supported weight-management program in people with relatively recent diabetes who were not using insulin. Its result cannot settle comparisons with every other dietary approach, medication strategy or metabolic operation. Taylor's work on liver and pancreas fat offers a mechanism for improvement in some people, but explaining a mechanism is not predicting an individual's chance of remission. Ask whether a proposed service has relevant evidence, clinical supervision and a maintenance plan. Continuing effective treatment or resuming it when glucose rises is a health decision, not failure to win a remission label.

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial Diet intervention links longer remissions of type 2 diabetes and improved health Consensus report: definition and interpretation of remission in type 2 diabetes Professor Roy Taylor — Newcastle Magnetic Resonance Centre 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

Check common diabetes claims

Established means the claim is supported within the stated limits. Not means the claim overreaches the evidence. Talk means a popular saying should not guide care.

Use laboratory testing and the clinical history together

Claim: 'Type 2 diabetes is named with blood tests such as A1C and fasting glucose.' Verdict: established, with a distinction. These tests can establish diabetes, with confirmation when needed; history and sometimes additional testing identify the type. A tired afternoon or a high home reading is a reason to seek assessment, not a completed diagnosis. Knowing which question the test answers prevents an adult with another diabetes type from being assumed to have type 2.

2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 Diabetes Tests & Diagnosis

Ask about supported prevention when glucose is elevated

Claim: 'A structured lifestyle program can reduce new diabetes in high-risk adults.' Verdict: established. DPP compared an intensive supported intervention with placebo and metformin, rather than simply comparing people who intended to be healthy with those who did not. Its percentage reductions describe incidence in the groups studied. A prevention service should be judged by the support it delivers and whom it serves, not by a trial statistic used as an individual guarantee.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin Diabetes Prevention Program (DPP)

Require evidence before trusting a universal reversal promise

Claim: 'A supplement can reverse type 2 diabetes for everyone.' Verdict: not. NCCIH describes limited and inconsistent evidence for supplements, including small studies with differing products and outcomes; possible glucose effects do not establish universal remission or a cure. Supplements can interact with medicines or have adverse effects. DiRECT's remission result came from a supervised clinical program, not a bottled product. Bring supplement questions to the care team and do not replace effective diabetes treatment with a marketing claim.

Diabetes and Dietary Supplements: What You Need To Know Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Keep lifestyle benefits tied to the outcomes actually shown

Claim: 'Intensive lifestyle always prevents heart attacks in type 2 diabetes.' Verdict: not. Look AHEAD did not significantly reduce its primary cardiovascular outcome compared with diabetes support and education despite improvements in weight and other measures. Better fitness or glucose is useful without proving the claim about heart events. Retain lifestyle care and discuss blood pressure, cholesterol and medicines with demonstrated benefits where relevant; neither the positive markers nor the negative primary result should be stretched into an all-or-nothing conclusion.

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes Approach to Managing CKD in Diabetes

Let individual needs guide the first medicine

Claim: 'Everyone with type 2 diabetes must start metformin and nothing else.' Verdict: not. Current ADA guidance includes condition-specific heart and kidney protection, glucose and weight goals, and individual safety and access. Metformin remains an important option, but a universal single-drug rule misses those differences. The prescribing decision needs the full health history and a discussion of what the person can obtain and tolerate.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

Recognize remission as a supported result with a defined meaning

Claim: 'Some people in a supervised formula-diet trial reached remission.' Verdict: established. DiRECT found 46% versus 4% remission at one year using its original two-month medication-free criterion. The later consensus uses at least three months. Neither definition means a single normal reading proves permanent recovery. Ask which definition and follow-up period a headline uses before comparing results.

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial Consensus report: definition and interpretation of remission in type 2 diabetes

Keep screening appointments even when you feel well

Claim: 'If you feel fine you can skip eye and kidney screening.' Verdict: talk. Early changes may produce no pain or obvious loss of function, so a retinal examination and urine and blood kidney tests provide information that symptoms cannot. Foot checks add sensation, skin and circulation information. Feeling well is useful news, but it cannot stand in for these different assessments.

Diabetic Eye Disease Diabetic Kidney Disease Diabetes & Foot Problems

Treat insulin as help for the body's needs

A popular saying treats needing insulin as proof that someone failed. That is not a clinical finding. Type 2 diabetes includes inadequate insulin supply relative to need, and ADA guidance includes insulin when the clinical situation warrants it. William Polonsky's Behavioral Diabetes Institute offers education on concerns about insulin and the emotional burden of diabetes. Discuss fear, inconvenience or stigma openly so they can be addressed. A change in treatment reflects a care need, not a judgment about effort or character.

Symptoms & Causes of Diabetes 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Healthcare Professionals Resources — Behavioral Diabetes Institute

Know when to get help

Get a low-glucose plan before you need it

NIDDK describes hypoglycemia as glucose below the healthy range for the person; below 70 mg/dL is a common alert level, but your team should explain your threshold and response. Insulin, sulfonylureas and other insulin-releasing medicines carry particular risk. Missed or delayed meals, alcohol, more activity than usual, illness or changing kidney function can alter that risk. Shakiness, sweating, hunger, confusion or trouble speaking may occur, and some people have little warning. Obtain written instructions for checking and treating a low, when to call for help, and whether rescue glucagon is needed. Someone close to you should know the emergency plan if you cannot treat yourself. Repeated lows deserve a prompt treatment review rather than acceptance as the price of good control.

Low Blood Glucose (Hypoglycemia)9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

Seek urgent care for severe symptoms and use your illness plan

Severe vomiting with inability to keep fluids down, trouble breathing, severe confusion or loss of consciousness needs urgent medical help. Chest pain also needs urgent assessment. CDC explains that diabetic ketoacidosis, an emergency caused by insufficient insulin and accumulating acids called ketones, can occur in type 2 as well as type 1 diabetes. The ADA also notes that SGLT2-associated ketoacidosis can occur without the very high glucose someone might expect. Ask the care team for illness and procedure instructions specific to your medicines before an illness or operation. Do not improvise medicine changes from this article, and do not wait for a reassuring A1C or sensor number when severe symptoms are present.

Diabetic Ketoacidosis Symptoms & Causes of Diabetes Low Blood Glucose (Hypoglycemia)9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

Use this reading to prepare for qualified care

This is a reading companion, not a diagnosis, diet prescription, or medicine list. High glucose, thirst, unexplained weight change, or known diabetes belong with a qualified clinician. Do not start, stop, or change medicines from this text. Severe vomiting, confusion, or chest pain needs urgent care. This page does not treat one person or promise reversal.

Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

Diabetes Tests & Diagnosis 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Diabetic Ketoacidosis

Prepare one useful care conversation

Bring your glucose results and main question to your clinician

Make a short visit note with your latest A1C or laboratory glucose result, its date and units, any symptoms, your current medicines and supplements, and the first question you want answered. A useful question might be whether confirmation is complete, whether a prevention service fits, or what a treatment is protecting. If you already have diabetes, include relevant eye, kidney and foot check dates. Bring home readings only as part of the monitoring plan you have been given. The purpose is to connect the evidence to a qualified assessment of your circumstances, not to use a page as a diagnosis or select a medicine yourself.

Diabetes Tests & Diagnosis 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 Diabetic Kidney Disease Diabetic Eye Disease Diabetes & Foot Problems

Try asking which support matches your current stage

With prediabetes, ask whether a recognized prevention program is appropriate and what coaching and follow-up it offers. With established diabetes, ask how food, activity, medicines and diabetes education will work together. Name one practical obstacle, such as shift work, food access or cost, so the discussion can include it. DPP supports structured prevention in high-risk adults; diabetes self-management education helps make established care understandable. These are different services for different jobs, not interchangeable challenges with the same promised outcome.

Diabetes Prevention Program (DPP)Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Healthy Living with Diabetes

Try confirming the next checks and the safety instructions

Before the visit ends, ask when the next glucose review, eye assessment, kidney tests and foot assessment are due. If your medicines can cause low glucose, ask the clinician or educator to explain the recognition, response and emergency plan in words you can repeat back. Ask whom to contact about repeated lows, illness, side effects or difficulty obtaining treatment. A written next step and contact point make the plan easier to keep when life changes. The treating team sets the timing and treatment; your preparation helps identify gaps and unanswered questions.

Low Blood Glucose (Hypoglycemia)Diabetic Kidney Disease Diabetic Eye Disease Diabetes & Foot Problems 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

References for this topic

Sources and context

Symptoms & Causes of Diabetes ↗
id
type-2-diabetes--niddk-mechanism — Symptoms & Causes of Diabetes
kind
official
accessed at
2026-10-01
supports
Insulin resistance plus insufficient insulin supply, slow or absent type 2 symptoms, adult type 1 and possible ketoacidosis.
limitations
Public education, not individual diagnosis or a comprehensive account of every cause.
original id
niddk-mechanism
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 ↗
id
type-2-diabetes--ada-diagnosis-2026 — 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
kind
guideline
accessed at
2026-10-01
supports
Tables 2.1 and 2.2; confirming diagnosis with two abnormal results together or separately; discordant tests; A1C interference; type classification; prevention evidence largely from impaired-glucose-tolerance populations.
limitations
Professional guidance; relevant full-text sections informed this article. It is not an individual assessment.
original id
ada-diagnosis-2026
Diabetes Tests & Diagnosis ↗
id
type-2-diabetes--niddk-tests — Diabetes Tests & Diagnosis
kind
official
accessed at
2026-10-01
supports
Test meanings, nonpregnant diagnostic and prediabetes ranges, confirmation, home-meter limitation and classification.
limitations
Page last reviewed July 2022; current diagnostic details were cross-checked against ADA 2026.
original id
niddk-tests
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin ↗
id
type-2-diabetes--dpp-2002 — Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
kind
study
accessed at
2026-10-01
supports
3,234 high-risk adults; trial goals; mean 2.8 years; incidence 4.8/7.8/11.0 per 100 person-years; 58%/31% relative reductions.
limitations
This account relies on the primary abstract; the full paper was not reviewed. Participants had elevated fasting and post-load glucose, so the findings do not cover every presentation of prediabetes based on A1C alone.
original id
dpp-2002
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 ↗
id
type-2-diabetes--ada-medicines-2026 — 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
kind
guideline
accessed at
2026-10-01
supports
Recommendations 9.5–9.23 and Table 9.2: individualized treatment; cardiovascular/kidney benefits irrespective of A1C where indicated; agent-specific outcomes, safety, cost, insulin role and SGLT2 ketoacidosis warning.
limitations
Relevant full-text sections informed this article. These are professional recommendations, not a dose guide or individual prescription; evidence for specific medicines must remain distinct from claims about entire drug classes.
original id
ada-medicines-2026
Healthy Living with Diabetes ↗
id
type-2-diabetes--niddk-living — Healthy Living with Diabetes
kind
official
accessed at
2026-10-01
supports
Meal patterns, movement, sleep, registered-dietitian support, gradual changes and individualized daily-care discussion.
limitations
Public education; no individual exercise clearance, restrictive diet, calorie target or supplement regimen inferred.
original id
niddk-living
The Price of Insulin: A Q&A with Kasia Lipska ↗
id
type-2-diabetes--lipska-cost — The Price of Insulin: A Q&A with Kasia Lipska
kind
professional
accessed at
2026-10-01
supports
Public explanation of insulin affordability as a barrier that should be discussed with the care team.
limitations
Historical interview and research setting, not a current price list, current insurance policy or nationwide prevalence estimate.
original id
lipska-cost
Diabetic Kidney Disease ↗
id
type-2-diabetes--niddk-kidneys — Diabetic Kidney Disease
kind
official
accessed at
2026-10-01
supports
Asymptomatic early disease; urine albumin and blood filtration tests; yearly testing in type 2 diabetes.
limitations
General education; personal monitoring and treatment depend on results and other conditions.
original id
niddk-kidneys
Diabetic Eye Disease ↗
id
type-2-diabetes--niddk-eyes — Diabetic Eye Disease
kind
official
accessed at
2026-10-01
supports
Early retinal disease may have no pain or vision change; dilated examination and prompt review of sudden vision changes.
limitations
Eye-care schedule and treatment require assessment; feeling well does not establish absence of damage.
original id
niddk-eyes
Diabetes & Foot Problems ↗
id
type-2-diabetes--niddk-feet — Diabetes & Foot Problems
kind
official
accessed at
2026-10-01
supports
Loss of sensation, circulation and hidden injuries; foot assessment and symptoms between visits.
limitations
General foot-care education, not wound treatment or an individual examination.
original id
niddk-feet
Low Blood Glucose (Hypoglycemia) ↗
id
type-2-diabetes--niddk-low — Low Blood Glucose (Hypoglycemia)
kind
official
accessed at
2026-10-01
supports
Common alert level; insulin/insulin-releasing medicines; symptoms, absent warnings, meals/activity/alcohol/illness and recognition/response planning including rescue glucagon.
limitations
Official education. Individual response instructions must come from treating team; the article does not replace emergency care.
original id
niddk-low
Diabetes Prevention Program (DPP) ↗
id
type-2-diabetes--niddk-dpp — Diabetes Prevention Program (DPP)
kind
official
accessed at
2026-10-01
supports
NIH trial overview, supported prevention, original intervention and follow-up context.
limitations
Official study translation, not a guarantee for an individual or proof that all commercial programs reproduce DPP.
original id
niddk-dpp
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial ↗
id
type-2-diabetes--dppos-2025 — Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial
kind
study
accessed at
2026-10-01
supports
3,195 participants; varying observation periods; group crossover to lifestyle support; mean and median diabetes-free-survival gains distinguished.
limitations
This account relies on the primary abstract; the full paper was not reviewed. It follows original assignments after interventions changed, rather than comparing unchanged treatments for 21 years.
original id
dppos-2025
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) ↗
id
type-2-diabetes--ukpds-33 — Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
kind
study
accessed at
2026-10-01
supports
3,867 newly diagnosed adults; approximately ten years; 25% relative reduction in microvascular endpoints; more hypoglycemia and weight gain.
limitations
The available primary abstract was truncated at the end; the full paper was not reviewed. The earlier treatment era and population limit its use for choosing modern medicines.
original id
ukpds-33
Approach to Managing CKD in Diabetes ↗
id
type-2-diabetes--ada-kidney-2026 — Approach to Managing CKD in Diabetes
kind
guideline
accessed at
2026-10-01
supports
ADA 2026 professional infographic connects glucose, blood pressure, cardiovascular care and therapies with demonstrated kidney benefits.
limitations
One-page professional summary opened; specific thresholds and prescribing sequences remain outside this article's guidance.
original id
ada-kidney-2026
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial ↗
id
type-2-diabetes--direct-2018 — Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
kind
study
accessed at
2026-10-01
supports
49 practices; eligibility; supported intervention components; 46% versus 4% remission at one year; original two-month medicine-free criterion.
limitations
Opened primary PubMed abstract, not full text. Selected population, open-label design, supervised medicine changes; no home diet instructions or universal remission probability.
original id
direct-2018
Consensus report: definition and interpretation of remission in type 2 diabetes ↗
id
type-2-diabetes--remission-consensus — Consensus report: definition and interpretation of remission in type 2 diabetes
kind
guideline
accessed at
2026-10-01
supports
Remission terminology; usual A1C <6.5% criterion measured at least three months after glucose-lowering treatment cessation; active observation.
limitations
Opened consensus abstract; formal terminology does not establish permanent cure or mandate stopping treatment. Ongoing screening also supported by relevant NIDDK pages.
original id
remission-consensus
Diet intervention links longer remissions of type 2 diabetes and improved health ↗
id
type-2-diabetes--direct-five-year-official — Diet intervention links longer remissions of type 2 diabetes and improved health
kind
official
accessed at
2026-10-01
supports
University report of observational DiRECT extension, remaining participants, maintenance support, weight regain and continuing remission in some people.
limitations
Official investigator-institution report of the 2024 extension, not independently read full trial paper. Article deliberately avoids hospital-event claims, causal interpretations and treating the remaining subgroup as the entire original cohort.
original id
direct-five-year-official
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes ↗
id
type-2-diabetes--look-ahead — Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
kind
study
accessed at
2026-10-01
supports
5,145 adults; median 9.6 years; weight/A1C/fitness improvement; primary event definition; event rates, hazard ratio and confidence interval.
limitations
This account relies on the primary abstract; the full paper was not reviewed. The primary cardiovascular result does not establish that lifestyle care has no benefits.
original id
look-ahead
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report ↗
id
type-2-diabetes--nutrition-consensus — Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
kind
guideline
accessed at
2026-10-01
supports
Evert-led consensus, individualized macronutrient mix, carbohydrate quality, definitions varying by approach and registered-dietitian nutrition therapy.
limitations
Relevant full-text sections of the 2019 consensus explain concepts consistent with later ADA/EASD guidance; they are not a personalized diet prescription.
original id
nutrition-consensus
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) ↗
id
type-2-diabetes--ada-easd-2022 — Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
kind
guideline
accessed at
2026-10-01
supports
Nutrition therapy; different eating patterns; short-term versus longer-term carbohydrate findings; fasting and medication safety; diabetes education and organ-protection framework.
limitations
Relevant sections of the 2022 consensus informed this article; ADA 2026 supplies the newer medication guidance.
original id
ada-easd-2022
Monica Peek, MD, MPH — UChicago Medicine ↗
id
type-2-diabetes--peek-profile — Monica Peek, MD, MPH — UChicago Medicine
kind
professional
accessed at
2026-10-01
supports
Verified internal-medicine role, diabetes disparities research, community education and informed shared decision-making.
limitations
Professional profile provides practice context and credentials, not independent efficacy evidence for a treatment.
original id
peek-profile
Healthcare Professionals Resources — Behavioral Diabetes Institute ↗
id
type-2-diabetes--bdi-resources — Healthcare Professionals Resources — Behavioral Diabetes Institute
kind
professional
accessed at
2026-10-01
supports
Named Polonsky education addressing diabetes distress, medication barriers, insulin concerns, hypoglycemia worry and environmental barriers.
limitations
Resource descriptions opened; linked training videos not watched. Practical professional perspective does not establish clinical-event effects.
original id
bdi-resources
Effects of intensive glucose lowering in type 2 diabetes ↗
id
type-2-diabetes--accord-2008 — Effects of intensive glucose lowering in type 2 diabetes
kind
study
accessed at
2026-10-01
supports
10,251 high-risk adults; intensive A1C target <6.0%; mortality-driven early stop at 3.5 years; more assisted hypoglycemia and major weight gain.
limitations
This account relies on the primary abstract. The intensive strategy does not isolate a mechanism of harm or show that every low A1C is dangerous.
original id
accord-2008
Professor Roy Taylor — Newcastle Magnetic Resonance Centre ↗
id
type-2-diabetes--taylor-profile — Professor Roy Taylor — Newcastle Magnetic Resonance Centre
kind
professional
accessed at
2026-10-01
supports
Verified emeritus role, mechanism/remission research, retinal-screening contribution and public-information link.
limitations
Researcher's account of mechanism and contribution; article deliberately does not adopt his profile's broad causal language as a universal prediction.
original id
taylor-profile
Diabetes and Dietary Supplements: What You Need To Know ↗
id
type-2-diabetes--nccih-supplements — Diabetes and Dietary Supplements: What You Need To Know
kind
official
accessed at
2026-10-01
supports
Weak/inconsistent supplement evidence, heterogeneous trials, possible interactions and harms, no replacement for proven treatment or universal cure claim.
limitations
Official evidence summary; possible effects on particular markers are not remission or outcome evidence. Older prevalence/age statistics on this page are not adopted.
original id
nccih-supplements
Diabetic Ketoacidosis ↗
id
type-2-diabetes--cdc-dka — Diabetic Ketoacidosis
kind
official
accessed at
2026-10-01
supports
DKA can occur in type 2; ketone mechanism; urgent help for vomiting/inability to keep fluids, breathing trouble and severe illness.
limitations
Official emergency education. The article does not supply insulin adjustments or replace an individualized sick-day plan.
original id
cdc-dka
r/diabetes_t2: remission — question about weight loss versus carbohydrate restriction ↗
id
type-2-diabetes--remission-question-signal — r/diabetes_t2: remission — question about weight loss versus carbohydrate restriction
kind
question_signal
accessed at
2026-10-01
supports
Opened reader question motivated clear separation of calorie/weight change, eating pattern, glucose control and remission.
limitations
Older thread inspected now; self-reports and comments are not verified clinical evidence, current demand measurement or dietary guidance. Not used as factual support for an article item.
original id
remission-question-signal

Professional perspectives

William C. Knowler
MD, DrPH; NIDDK Scientist Emeritus, Phoenix Epidemiology & Clinical Research Branch
Public usefulness
Official Research in Plain Language explanation makes prevention trials and their uncertainty understandable.
Contribution
DPP and DPPOS investigator; grounds the distinction between lower incidence and permanent prevention.
Scope and limits
Group trial results in high-risk adults do not predict every reader's risk.
Reviewed
2026-10-01
David M. Nathan
MD; director of the Diabetes Clinical Research Center at Massachusetts General Hospital; Harvard professor of medicine
Public usefulness
Mass General's public Advances in Motion profile connects readers to clinical research and education; DPP authorship verified in primary study.
Contribution
Clinical trial work helps explain prevention and treatment comparisons without reducing them to slogans.
Scope and limits
Clinical-research leadership is not personal treatment advice or endorsement of a commercial program.
Reviewed
2026-10-01
Melanie J. Davies
MBChB, MD; professor of diabetes medicine, University of Leicester; honorary consultant diabetologist
Public usefulness
Public university profile describes self-management, screening and prevention research; ADA/EASD consensus is an accessible professional teaching source.
Contribution
Lead author of 2022 consensus; connects nutrition, education and medicines in person-centered care.
Scope and limits
Consensus recommendations are conditional guidance, not proof that every option helps every person.
Reviewed
2026-10-01
Kamlesh Khunti
Professor of primary care diabetes and vascular medicine, University of Leicester
Public usefulness
University and Leicester Diabetes Centre public profiles describe primary-care, risk-assessment and ethnic-health work; university page links professional social profile.
Contribution
Examines how primary care, coexisting conditions and differences among populations affect the interpretation of diabetes evidence.
Scope and limits
Real-world associations and risk tools are not interchangeable with randomized treatment effects.
Reviewed
2026-10-01
Silvio E. Inzucchi
MD; professor of medicine in endocrinology, Yale School of Medicine
Public usefulness
Official Yale profile provides clinical and teaching background, publications and public links on diabetes care.
Contribution
Treatment-consensus and cardiovascular trial work helps distinguish glucose lowering from organ protection.
Scope and limits
Outcome evidence belongs to specific agents and populations; a named clinician cannot substitute for prescribing assessment.
Reviewed
2026-10-01
Anne L. Peters
MD; USC professor of medicine and director of USC Clinical Diabetes Programs
Public usefulness
Official profile records diabetes books, public programs, exercise media and clinical education.
Contribution
Adds practical monitoring, exercise and technology-safety perspective; Look AHEAD involvement is documented on the official profile.
Scope and limits
Public education and device expertise do not establish that every lifestyle intervention prevents heart events.
Reviewed
2026-10-01
John B. Buse
MD, PhD; endocrinology-trained physician; UNC diabetes-center director as identified in ADA's 2024 professional award profile
Public usefulness
ADA's public profile explains clinical/translational work; the ADA/EASD consensus provides accessible professional teaching with his authorship.
Contribution
Consensus and clinical trial contribution supports shared treatment choices and careful assessment of safety and efficacy.
Scope and limits
The role is documented in a 2024 professional profile, rather than a current appointment check; it does not supply an individual recommendation.
Reviewed
2026-10-01
Michael E. J. Lean
MD; University of Glasgow human-nutrition researcher and consultant physician
Public usefulness
University's public DiRECT explanations and listed lectures translate remission research for wider audiences.
Contribution
DiRECT investigator; keeps formula replacement, reintroduction, supervision and maintenance together.
Scope and limits
Selected trial eligibility and remaining extension participants limit generalization; remission is not universal.
Reviewed
2026-10-01
Roy Taylor
MD, FRCP; emeritus professor of medicine and metabolism, Newcastle University
Public usefulness
Official profile links public diabetes-remission information and explains retinal-screening and mechanism work.
Contribution
Connects liver/pancreas fat research to DiRECT while distinguishing a mechanism from a personal remission forecast.
Scope and limits
Mechanistic account and investigator interpretation do not prove that all type 2 diabetes shares one reversible cause or endorse products using his name.
Reviewed
2026-10-01
Naveed Sattar
Physician, PhD; University of Glasgow professor of cardiometabolic medicine and honorary consultant
Public usefulness
Official profile documents international teaching and guideline contributions; public cardiometabolic explanation helps frame glucose beside heart and kidney outcomes.
Contribution
DiRECT and cardiovascular/outcome-trial contributions provide a bridge between weight, diabetes and organ risk.
Scope and limits
Research and guideline roles do not make every drug in a class equivalent; industry-funded trial roles require evidence to be judged on design and results.
Reviewed
2026-10-01
Hertzel C. Gerstein
Endocrinologist; McMaster professor of medicine; PHRI senior scientist and diabetes-program lead
Public usefulness
PHRI's public study and biography pages explain diabetes outcome trials and the importance of measuring events.
Contribution
ACCORD and other outcome-trial leadership helps clarify why glucose targets and cardiovascular outcomes require separate evaluation.
Scope and limits
One intensive-strategy trial does not show that every low A1C is unsafe or identify a single cause of mortality.
Reviewed
2026-10-01
Deborah J. Wexler
MD, MSc; board-certified endocrinology, diabetes and metabolism physician at Mass General Brigham
Public usefulness
Official profile describes clinical-effectiveness research, ADA/EASD consensus authorship and NIDDK Diabetes in America editing.
Contribution
Her work emphasizes clinical effectiveness and care that patients can use in daily life, alongside laboratory measures.
Scope and limits
Professional interpretation is not a new trial or proof of a particular treatment for an individual.
Reviewed
2026-10-01
Rury R. Holman
Physician; Oxford professor of diabetic medicine and Diabetes Trials Unit emeritus director
Public usefulness
Official trials-unit profile links manuscripts and conference work and explains UKPDS risk tools used in evidence assessment.
Contribution
UKPDS chief investigator; preserves the microvascular outcome and safety tradeoff behind glucose control.
Scope and limits
Historical treatment policy and risk models are not a modern drug menu or an individual complication forecast.
Reviewed
2026-10-01
Alison B. Evert
MS, RDN, CDCES, FADCES; registered dietitian nutritionist and diabetes educator
Public usefulness
Official WSU profile describes nutrition education, telemedicine and embedding educators in primary care; lead author of accessible ADA nutrition consensus.
Contribution
Adds dietitian perspective, individualized eating patterns and the difference between practical support and a forbidden-food list.
Scope and limits
A 2019 consensus and educator profile do not set an individual's diet or establish a mandatory macronutrient ratio.
Reviewed
2026-10-01
Kasia J. Lipska
MD, MHS; Yale associate professor of medicine, endocrinologist and clinical investigator
Public usefulness
Yale's public insulin-cost Q&A and official research profile explain affordability and severe-hypoglycemia concerns.
Contribution
Keeps treatment burden, older-adult safety and access in discussion of glucose targets and medication choice.
Scope and limits
Historical local affordability research is not current national pricing or prevalence; observational harms require careful interpretation.
Reviewed
2026-10-01
Monica E. Peek
MD, MPH; UChicago internal-medicine physician and professor; Chicago Center for Diabetes Translational Research associate director
Public usefulness
Official patient-facing video transcript and profile describe community education and shared decisions in diabetes care.
Contribution
Brings access, racial/cultural barriers and informed patient participation into the practical follow-up conversation.
Scope and limits
Profile describes professional practice and research interests, not randomized proof for a particular intervention.
Reviewed
2026-10-01
William H. Polonsky
PhD; Behavioral Diabetes Institute president; professional diabetes-psychosocial educator
Public usefulness
BDI's opened resource page lists his public professional education on diabetes distress, insulin concerns, motivation and medication barriers.
Contribution
Supports respectful language about insulin and bringing emotional/practical barriers to the care team.
Scope and limits
Resource descriptions were read, not the linked videos; emotional support does not replace clinical treatment or prove event prevention.
Reviewed
2026-10-01

Keep this topic in view

Preserved original record

The earlier public profile is preserved separately from the current article. It may contain superseded wording and is not newly checked material.

Read the full original profile

slug

type-2-diabetes

name

Type 2 diabetes

browse Line

Understand A1C and fasting glucose tests, and what diabetes prevention trials found.

photo

/learn/assets/topics/type-2-diabetes.jpg

photo Alt

An adult at a table with a water glass and a simple meal, looking at a paper list in daylight

aliases

type 2
T2D
prediabetes
A1C
HbA1c
diabetes reversal
metformin
GLP-1 diabetes

family

body

heat

mid

talk

Sources

most Discussed

true

first Line

Type 2 diabetes develops when the body resists insulin and cannot make enough of it to keep blood glucose in range. Prediabetes means glucose is above the usual range but below diabetes thresholds, with a higher future risk that can often be reduced.

why Line

feel Words

a1c
fasting glucose
ogtt
prediabetes
diagnosis
prediabetes
prevention
DPP

common Picture

lead
Name type 2 diabetes with the tests the field uses
why
Blood tests establish diabetes; they do not by themselves establish which type it is. Common adult thresholds are A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL, or a two-hour oral glucose-tolerance result at least 200 mg/dL. Random plasma glucose at least 200 mg/dL with classic symptoms is another diagnostic route. Without clear symptoms or a hyperglycemic crisis, abnormal results usually need confirmation. Prediabetes includes A1C 5.7–6.4%. A clinician interprets the result with the history, since pregnancy, blood conditions and other factors can change how a test should be used.
lead
Ask about prevention when glucose is already in the prediabetes range
why
Prediabetes means glucose is high enough to raise later diabetes risk without meeting the diabetes cut. The Diabetes Prevention Program, led for publication by Knowler, found that a structured lifestyle program reduced new diabetes by 58 percent versus placebo in adults at high risk, with metformin also reducing incidence by 31 percent. Nathan's DPP teaching treats that as a group prevention result, not a home challenge brand. Bring your numbers to a clinician and ask which prevention path fits rather than buying a detox.
lead
Build daily care around food, movement, medicines, and follow-up
why
After diagnosis, care is a mix of eating pattern, activity, medicines when needed, and screening for eyes, kidneys, feet, and heart. ADA Standards, with El Sayed and Gabbay among named society authors, now individualize first medicines, including SGLT2 and GLP-1 options when heart or kidney disease is part of the picture. Inzucchi and Davies have spent years explaining that sequence as shared decision, not as a single mandatory pill. The choice and amount depend on individual health, current medicines, and monitoring needs.
lead
Keep eyes, feet, kidneys, and low-glucose risk in the same plan
why
Type 2 diabetes can damage small vessels in the eyes and kidneys, affect nerves and raise cardiovascular risk. UKPDS, with Holman among its investigators, showed that better glucose control reduced microvascular complications in the trial population. Later cardiovascular trials help explain why heart and kidney protection sit beside glucose numbers. Insulin and medicines that stimulate insulin release can also cause low glucose, especially when meals, activity or illness change. A recognition and response plan accounts for those medicines and circumstances so that routine care addresses both long-term damage and immediate treatment-related risk.

situation Quick Answers

- label
  Tests
  value
  A1C and plasma-glucose tests establish diabetes; history helps determine its type.
- label
  Confirmation
  value
  An abnormal result usually needs confirmation when clear symptoms are absent.
- label
  What prediabetes means
  value
  Glucose is above the usual range, with higher future risk rather than inevitable diabetes.
- label
  What has evidence
  value
  Structured lifestyle support reduced new diabetes in the high-risk adults studied in DPP.
- label
  Different goals
  value
  Food, activity and medicines can address glucose, weight, heart and kidney needs.
- label
  Make the plan usable
  value
  Know what each part is for and raise side effects, cost or access problems at follow-up.
- label
  Why screening matters
  value
  Early eye and kidney damage may have no symptoms, and reduced foot sensation can hide injury.
- label
  Low-glucose planning
  value
  People using insulin or insulin-releasing medicines need a clear recognition and response plan.

picture Lead

Name type 2 diabetes with the tests the field uses

watch For

what People Say

Blood tests establish diabetes; the history helps establish its type. A1C and glucose tests answer related but different questions about blood sugar. A1C reflects a longer period, while fasting and oral glucose-tolerance tests measure glucose at defined times. Results usually require confirmation unless the clinical presentation is unequivocal. Identifying type 2 also depends on the clinical picture, rather than assuming every adult with a high result has the same condition. Bring the laboratory report and relevant symptoms so the units, timing and next step are clear.
Treat structured lifestyle as a documented prevention option. Knowler's DPP trial found a 58 percent reduction in new diabetes with a structured lifestyle program versus placebo in high-risk adults. Nathan's DPP follow-up teaching keeps that as a group prevention result. CDC's National DPP is a later translation of the same idea. It is not a social-media 30-day challenge.
Treat glucose control as protection for eyes, kidneys, and nerves. UKPDS 33 found that intensive glucose control reduced microvascular complications in newly diagnosed type 2 diabetes. Holman's later UKPDS follow-up teaching keeps that microvascular result in view. ADA still treats glucose, blood pressure, and cholesterol as a set. Trial averages are not a personal complication forecast.
Individualize medicines with heart and kidney history in the room. ADA Standards now match first medicines to heart failure, kidney disease, and weight goals as well as to glucose. Inzucchi and Davies helped write the ADA and EASD consensus that moved SGLT2 and GLP-1 medicines forward for people with cardiorenal disease. Rosenstock's trial work is one reason those classes have outcome data. Product choice and dose still belong with a prescriber.
Treat remission as a trial result in selected people, not a slogan. Lean's DiRECT trial found that a total-diet-replacement program then stepped food reintroduction led to remission, meaning A1C under 6.5 percent off medicines, in a substantial share of the intervention group at one year. Taylor's liver-and-pancreas research is the mechanism story attached to that trial. Remission was not universal and required a supervised program. A juice cleanse is not DiRECT.
Keep Look AHEAD in view when someone sells lifestyle as heart-event prevention. Look AHEAD tested intensive lifestyle versus diabetes support in type 2 diabetes and did not reduce cardiovascular events as the primary outcome. Wexler's later teaching still treats eating pattern and activity as care, just not as a proven event-prevention substitute for the rest of the plan. Peters public education makes the same practical cut. Lifestyle remains part of care for glucose, function, and weight.

disputed Notes

Match first medicine to the person rather than to a single historical default. Metformin remains a common starting medicine when cost, tolerance, and no strong cardiorenal indication point that way. ADA now elevates SGLT2 and GLP-1 options when heart failure, chronic kidney disease, or stroke history is present. Khunti and Sattar have argued in public evidence reviews that the old metformin-first slogan is too simple for some patients. The disagreement is sequence, not whether glucose care matters.
Treat low-carbohydrate patterns as one eating option with monitoring. Some clinicians use lower-carbohydrate patterns to lower glucose quickly, while ADA still frames eating as a pattern the person can repeat, with carbohydrate quality and overall calories in view. Davies consensus teaching does not crown one named diet as mandatory. Safety issues include low glucose if medicines are not adjusted. A clinician has to watch the medicines when the plate changes.
Read remission headlines with the DiRECT protocol attached. DiRECT used a formula diet, then stepped reintroduction, in people with shorter-duration type 2 diabetes and a BMI in a specified range. Taylor is careful that later weight regain can bring glucose back. Public reversal videos often skip those limits. Ask whether a local program actually resembles the trial.
Keep older versus newer cardiovascular-outcome trials in the same conversation. UKPDS answered microvascular questions in a different medicine era. Gerstein's ACCORD-related work and later GLP-1 and SGLT2 outcome trials changed how clinicians think about heart events. The live debate is how aggressively to chase a number versus using medicines with proven heart or kidney benefit. That is a specialist conversation, not a forum target.

talk Notes

Use a lab, not a supplement quiz, to name diabetes. A popular saying is that a tired afternoon plus a social-media list equals type 2 diabetes. ADA and CDC both start with named blood tests. Buse's teaching keeps confirmation in view. Symptoms can prompt a visit and still not finish the label.
Treat reversal videos as marketing until they match a trial. Online talk promises that one powder reverses diabetes. Lean's DiRECT result is a supervised food-replacement program in a selected group. NIDDK public pages still treat type 2 diabetes as a condition that needs medical care. A bottle is not a trial.
Keep insulin as one tool rather than as a moral last place. A saying treats insulin as proof that someone failed. ADA uses insulin when it is the right tool for glucose, illness, or later type 2 physiology. Peters public teaching makes the same practical cut. A medicine class is not a character grade.
Ask about eyes, feet, and kidneys even when glucose feels fine. People sometimes skip screening because they feel well. UKPDS and ADA both treat microvascular screening as part of ordinary care. Holman's follow-up teaching keeps that long view. Feeling fine is not a retinal exam.

how People Run It

Bring one glucose picture to a clinician. Write four short lines: the latest A1C or fasting number if you have one, thirst or vision changes, current medicines, and what you want help with first. ADA and CDC both start with tests and a history rather than with a detox. Knowler's DPP result is a reason to ask about prevention if you are in the prediabetes band. This is ordinary preparation, not a diagnosis.
Collect recent glucose numbers and medicines before the visit. Bring A1C, home readings, and a medicine list. ADA care starts with those facts. CDC public pages likewise want a clinician to interpret the tests. Notes are not a diagnosis.
Ask whether a prevention program or a medicine plan is the next step. If you are in the prediabetes range, ask about a DPP-style program. Knowler and Nathan supply the trial reason. If you already have diabetes, ask how food, activity, and medicines will be combined. Do not start a medicine from a video.
Ask when eyes, feet, and kidneys were last checked. ADA treats those screens as ordinary care. UKPDS is the historical reason glucose control is tied to small-vessel outcomes. If you use insulin or a sulfonylurea, also ask about low-glucose plans. A page cannot schedule the exam.

how People Keep It

Keep the test, units and timing together. An A1C result and a fasting glucose result measure different things. Save the report, whether confirmation is planned and how the clinician interpreted it; a home meter reading alone does not identify the type of diabetes.
A prevention program includes ongoing support. For prediabetes, ask what coaching, follow-up and practical help a program provides. DPP's benefit came from a structured intervention in high-risk adults; the trial percentages are not a prediction for every person.
Know the goal of each medicine. A plan may address glucose, weight, heart or kidney risk. Ask what each treatment is for and how benefits, side effects, affordability and access will be reviewed.
Remission still includes follow-up. The 2021 consensus generally defines remission as A1C below 6.5% at least three months after glucose-lowering medicines stop. This differs from DiRECT's original trial definition. Glucose can rise again, and screening continues; medicine changes need supervision.
Bring changes in the pattern to follow-up. A useful record includes glucose results, symptoms, medicine changes and practical barriers such as cost or missed meals. This helps the care team judge what needs adjusting instead of treating one number in isolation.

claims Notes

Use ADA thresholds to name diabetes and prediabetes. Claim: “Type 2 diabetes is named with blood tests such as A1C and fasting glucose” — established. A1C and plasma-glucose tests can establish diabetes, usually with confirmation when symptoms are absent. Clinical history and sometimes other testing determine the type. A home reading or symptom quiz cannot complete that process.
Ask about a prevention program when glucose is already high. Claim: “A structured lifestyle program can reduce new diabetes in high-risk adults” — established. Knowler's DPP found a 58 percent reduction in new diabetes with structured lifestyle versus placebo in high-risk adults. That is a group trial result, not a detox.
Treat reversal headlines as marketing until they match a trial. Claim: “A supplement can reverse type 2 diabetes for everyone” — not what the research found. No named supplement trial sits at the DiRECT or DPP bar. Lean's remission result used a supervised food-replacement program in selected people, not a bottle.
Keep lifestyle as care, not as proven event prevention by itself. Claim: “Intensive lifestyle always prevents heart attacks in type 2 diabetes” — not what the research found. Look AHEAD did not reduce cardiovascular events as its primary outcome despite better weight and fitness. Lifestyle still matters for glucose and function.
Match first medicines to heart, kidney, and glucose goals. Claim: “Everyone with type 2 diabetes must start metformin and nothing else” — not what the research found. ADA now individualizes first medicines, including SGLT 2 and GLP-1 options when cardiorenal disease is present. Metformin remains common when it fits. Sequence is shared decision.
Read remission as a trial result in selected people. Claim: “Some people in a supervised formula-diet trial reached remission” — established. DiRECT found remission at one year in 46% of the intervention group versus 4% of controls. Its selected participants followed a supervised program; the original definition required A1C below 6.5% after at least two months off diabetes medicines. The later consensus uses at least three months.
Keep eyes, feet, and kidneys in ordinary care even when you feel well. Claim: “If you feel fine you can skip eye and kidney screening” — popular talk. Eye and kidney damage can begin without obvious symptoms. Retinal examination, urine albumin and blood filtration tests answer questions that feeling well or checking A1C cannot. Foot checks add information about sensation, skin and circulation.

deep Dive

DPP tested a supported prevention program in people already at high risk. Knowler and colleagues randomized 3,234 adults with elevated fasting and post-load glucose to intensive lifestyle support, metformin or placebo. Over an average 2.8 years, new diabetes occurred at rates of 4.8, 7.8 and 11.0 cases per 100 person-years, respectively. The widely quoted 58% and 31% reductions are relative to placebo, not percentage-point reductions in everyone's risk. The lifestyle arm involved coaching and specific activity and weight goals. Its results explain why structured prevention deserves attention; a general promise to eat better is not the same intervention.
UKPDS links glucose control to complications while showing a treatment tradeoff. UKPDS 33 randomized 3,867 adults with newly diagnosed type 2 diabetes to an intensive or conventional treatment policy. Over about ten years, the intensive group had fewer small-vessel complications, including eye outcomes requiring treatment. It also had more low-glucose episodes and weight gain. This helps explain why long-term glucose control matters and why a lower number is not the only outcome to consider. The trial used an earlier generation of treatment strategies. Current decisions also consider heart and kidney outcomes, individual risk and what someone can safely sustain.
DiRECT studied remission through a supervised primary-care program. Lean and colleagues randomized 49 practices to intensive weight management or usual care. Participants were aged 20–65, had type 2 diabetes for less than six years, had BMI 27–45 and were not using insulin. The program combined formula-diet replacement, food reintroduction, weight-maintenance support and supervised medicine changes. At one year, 46% of the intervention group and 4% of controls met the trial's remission definition: A1C below 6.5% after at least two months off diabetes medicines. That result applies to a selected group and a supported program. Copying only its restrictive-diet phase leaves out essential parts of the intervention.
Weight and glucose improvement do not guarantee fewer cardiovascular events. Look AHEAD randomized 5,145 adults with overweight or obesity and type 2 diabetes to intensive lifestyle treatment or diabetes support and education. After a median 9.6 years, the intervention had produced more weight loss and better early glucose and fitness measures, but it had not significantly reduced the primary cardiovascular-event outcome. The result is specific to that comparison and outcome. It does not show that activity and eating patterns are pointless. It shows why studies should measure events directly instead of assuming that every improved risk marker necessarily delivers the same long-term benefit.
Different medicines can serve different goals in the same care plan. The ADA's 2026 Standards organize treatment around glucose, weight, heart and kidney needs as well as safety and access. A medicine may be considered for demonstrated heart or kidney benefit even when A1C is already near its goal. Conversely, a familiar medicine may remain useful because it is effective, affordable and tolerated. This explains why two people with the same A1C can receive different plans. The practical discussion is what each medicine is meant to accomplish, its likely adverse effects, what it costs and how its effect will be reviewed.
Read a heart or kidney claim by the outcome actually measured. Glucose lowering, fewer heart-failure admissions and slower kidney decline are different outcomes. A trial showing one does not automatically prove the others. The ADA's current recommendations identify therapies with demonstrated benefit for particular cardiovascular or kidney conditions, rather than assuming every product in a broad class has identical evidence. Useful questions are who joined the trial, what treatment it was compared with and which event changed. Those distinctions make a prescribing conversation more understandable while leaving medicine selection and monitoring with the treating clinician.
Know how the current treatment can cause low glucose. Insulin and medicines that make the pancreas release more insulin can lower glucose too far. Missed meals, illness, alcohol or unusually high activity can change that risk. NIDDK describes symptoms including shakiness, sweating, hunger, confusion and difficulty thinking clearly, while some people do not notice early warning signs. The care plan should explain how to check, respond and get help, including what somebody else should do if the person cannot treat themselves. Review that plan when medicines or eating patterns change. Repeated lows are a reason to contact the care team.
Screening looks for damage that may not hurt or feel different yet. Kidney checks usually combine urine albumin, which can reveal protein leakage, with a blood test estimating filtration. An eye examination looks for retinal changes that good day-to-day vision can miss. Foot assessment considers sensation, skin and circulation because reduced feeling can hide an injury. These checks answer different questions from an A1C result. Keep the results and next review dates together so gaps are easier to notice. The care team sets the schedule according to findings and history; new symptoms deserve attention between routine appointments.
Prevention can delay diabetes even when long-term risk remains. A 2025 DPP follow-up analyzed 3,195 original participants across a period extending to 21 years, with different follow-up lengths for individuals. Compared with the original placebo assignment, average diabetes-free survival was about two years longer after lifestyle assignment and 1.2 years longer after metformin assignment. This is a useful outcome even though many participants eventually developed diabetes. After the original trial, all groups were offered lifestyle training, so the follow-up is not a clean comparison of unchanged treatments for two decades. Read it as evidence about durable benefit and delay, rather than a lifetime guarantee.

related

nutrition
fitness
sleep

watch For Long

Good to know. This is a reading companion, not a diagnosis, diet prescription, or medicine list. High glucose, thirst, unexplained weight change, or known diabetes belong with a qualified clinician. Do not start, stop, or change medicines from this text. Severe vomiting, confusion, or chest pain needs urgent care. This page does not treat one person or promise reversal.
Not advice. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

sources

John Buse. endocrinologist and ADA guideline contributor
Silvio Inzucchi. endocrinologist; ADA/EASD hyperglycemia consensus
Melanie Davies. diabetologist; ADA/EASD consensus lead
Hertzel Gerstein. endocrinologist; cardiovascular outcome trials
Roy Taylor. physician-researcher; DiRECT mechanism and remission
Michael Lean. physician-nutrition researcher; DiRECT lead
William Knowler. epidemiologist; Diabetes Prevention Program
David Nathan. endocrinologist; DPP and glucose-trial leadership
Julio Rosenstock. endocrinologist; incretin and outcome trials
Anne Peters. endocrinologist; public type 2 education
Nuha El Sayed. endocrinologist; ADA Standards leadership
Robert Gabbay. endocrinologist; ADA practice translation
Kamlesh Khunti. primary-care diabetes researcher
Naveed Sattar. cardiometabolic researcher
Deborah Wexler. endocrinologist; clinical diabetes research
Rury Holman. diabetologist; UKPDS investigator

source Links

ADA-STANDARDS

name

American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes. Diabetes Care, current year.

kind

evidence

links

label
ADA
href
https://diabetesjournals.org/care

CDC-T2D

name

Centers for Disease Control and Prevention. Type 2 diabetes and prediabetes public pages, including the National DPP.

kind

evidence

links

label
CDC
href
https://www.cdc.gov/diabetes/

NIDDK-T2D

name

National Institute of Diabetes and Digestive and Kidney Diseases. Type 2 Diabetes public overview.

kind

evidence

links

label
NIDDK
href
https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/type-2-diabetes

DPP-2002

name

Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/11832527/

UKPDS-33

name

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/9742976/

DIRECT-2018

name

Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541-551.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/29221645/

LOOK-AHEAD-2013

name

Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-154.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/23796131/

ADA-EASD-CONSENSUS

name

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2022;45:2753-2786.

kind

evidence

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/36148880/

WHO-T2D

name

World Health Organization. Diabetes fact sheet and public classification pages.

kind

evidence

links

label
WHO
href
https://www.who.int/news-room/fact-sheets/detail/diabetes

NATIONAL-DPP

name

Centers for Disease Control and Prevention. National Diabetes Prevention Program overview.

kind

evidence

links

label
CDC DPP
href
https://www.cdc.gov/diabetes-prevention/

BUSE-T2D-2026

name

John Buse

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Buse+JB+diabetes

INZUCCHI-T2D-2026

name

Silvio Inzucchi

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Inzucchi+SE+diabetes

DAVIES-T2D-2026

name

Melanie Davies

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Davies+MJ+diabetes

GERSTEIN-T2D-2026

name

Hertzel Gerstein

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Gerstein+HC+diabetes

TAYLOR-T2D-2026

name

Roy Taylor

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Taylor+R+DiRECT

LEAN-T2D-2026

name

Michael Lean

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/29221645/

KNOWLER-T2D-2026

name

William Knowler

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/11832527/

NATHAN-T2D-2026

name

David Nathan

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Nathan+DM+diabetes+prevention

ROSENSTOCK-T2D-2026

name

Julio Rosenstock

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Rosenstock+J+diabetes

PETERS-T2D-2026

name

Anne Peters

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Peters+AL+diabetes

ELSAYED-T2D-2026

name

Nuha El Sayed

kind

professional

links

label
PubMed
href
https://diabetesjournals.org/care

GABBAY-T2D-2026

name

Robert Gabbay

kind

professional

links

label
PubMed
href
https://diabetesjournals.org/care

KHUNTI-T2D-2026

name

Kamlesh Khunti

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Khunti+K+diabetes

SATTAR-T2D-2026

name

Naveed Sattar

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Sattar+N+diabetes

WEXLER-T2D-2026

name

Deborah Wexler

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/?term=Wexler+DJ+diabetes

HOLMAN-T2D-2026

name

Rury Holman

kind

professional

links

label
PubMed
href
https://pubmed.ncbi.nlm.nih.gov/9742976/

NIDDK-DIAGNOSIS-CHECKED

name

NIDDK: Diabetes Tests and Diagnosis. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis

NIDDK-T2D-IDENTITY-CHECKED

name

NIDDK: Symptoms and Causes of Diabetes. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes

DPP-2002-CHECKED

name

Knowler et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/11832527/

ADA-2026-MEDICINES-CHECKED

name

ADA: Pharmacologic Approaches to Glycemic Treatment, Standards of Care 2026. Source

kind

evidence

links

label
Source
href
https://doi.org/10.2337/dc26-S009

NIDDK-EYE-CHECKED

name

NIDDK: Diabetic Eye Disease. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease

NIDDK-KIDNEY-CHECKED

name

NIDDK: Diabetic Kidney Disease. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease

NIDDK-FOOT-CHECKED

name

NIDDK: Diabetes and Foot Problems. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/foot-problems

NIDDK-HYPO-CHECKED

name

NIDDK: Low Blood Glucose, Hypoglycemia. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia

NIDDK-A1C-CHECKED

name

NIDDK: The A1C Test and Diabetes. Source

kind

evidence

links

label
Source
href
https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test

UKPDS-33-CHECKED

name

UKPDS 33: Intensive blood-glucose control and risk of complications. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/9742976/

ADA-2026-CARDIO-CHECKED

name

ADA: Cardiovascular Disease and Risk Management, Standards of Care 2026. Source

kind

evidence

links

label
Source
href
https://diabetesjournals.org/care/article/49/Supplement_1/S216/163933/10-Cardiovascular-Disease-and-Risk-Management

DIRECT-2018-CHECKED

name

Lean et al. Primary care-led weight management for remission of type 2 diabetes. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/29221645/

LOOK-AHEAD-CHECKED

name

Look AHEAD Research Group: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/23796131/

DPPOS-2025-CHECKED

name

Knowler et al. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/40311647/

DPPOS-2015-CHECKED

name

DPP Research Group: Long-term effects of lifestyle intervention or metformin over 15-year follow-up. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/26377054/

REMISSION-CONSENSUS-CHECKED

name

Riddle et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Source

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/34458934/

source Claims

watch For

ADA-STANDARDS
CDC-T2D
NIDDK-T2D

situations.name-tests

ADA-STANDARDS
CDC-T2D
NIDDK-T2D
BUSE-T2D-2026
NIDDK-DIAGNOSIS-CHECKED
NIDDK-A1C-CHECKED

situations.prevention

DPP-2002
KNOWLER-T2D-2026
NATHAN-T2D-2026
CDC-T2D
NIDDK-T2D-IDENTITY-CHECKED
DPP-2002-CHECKED

situations.daily-care

ADA-STANDARDS
ELSAYED-T2D-2026
GABBAY-T2D-2026
INZUCCHI-T2D-2026
DAVIES-T2D-2026
ADA-2026-MEDICINES-CHECKED

situations.complications

UKPDS-33
HOLMAN-T2D-2026
GERSTEIN-T2D-2026
ADA-STANDARDS
NIDDK-EYE-CHECKED
NIDDK-KIDNEY-CHECKED
NIDDK-FOOT-CHECKED
NIDDK-HYPO-CHECKED
UKPDS-33-CHECKED
ADA-2026-CARDIO-CHECKED

split.established.0

ADA-STANDARDS
CDC-T2D
NIDDK-T2D
BUSE-T2D-2026
NIDDK-DIAGNOSIS-CHECKED
NIDDK-A1C-CHECKED

split.established.1

DPP-2002
KNOWLER-T2D-2026
NATHAN-T2D-2026
CDC-T2D

split.established.2

UKPDS-33
HOLMAN-T2D-2026
ADA-STANDARDS

split.established.3

ADA-STANDARDS
INZUCCHI-T2D-2026
DAVIES-T2D-2026
ROSENSTOCK-T2D-2026

split.established.4

DIRECT-2018
LEAN-T2D-2026
TAYLOR-T2D-2026

split.established.5

LOOK-AHEAD-2013
WEXLER-T2D-2026
PETERS-T2D-2026

split.disputed.0

ADA-STANDARDS
KHUNTI-T2D-2026
SATTAR-T2D-2026

split.disputed.1

ADA-STANDARDS
DAVIES-T2D-2026

split.disputed.2

DIRECT-2018
TAYLOR-T2D-2026
LEAN-T2D-2026

split.disputed.3

UKPDS-33
GERSTEIN-T2D-2026
ADA-STANDARDS

split.talk.0

ADA-STANDARDS
CDC-T2D
BUSE-T2D-2026

split.talk.1

DIRECT-2018
NIDDK-T2D
LEAN-T2D-2026

split.talk.2

ADA-STANDARDS
PETERS-T2D-2026

split.talk.3

UKPDS-33
ADA-STANDARDS
HOLMAN-T2D-2026

move

ADA-STANDARDS
CDC-T2D
DPP-2002

try.0

ADA-STANDARDS
CDC-T2D

try.1

DPP-2002
KNOWLER-T2D-2026
NATHAN-T2D-2026

try.2

ADA-STANDARDS
UKPDS-33

keep.0

ADA-STANDARDS
CDC-T2D
NIDDK-A1C-CHECKED

keep.1

DPP-2002
CDC-T2D
DPP-2002-CHECKED

keep.2

INZUCCHI-T2D-2026
DAVIES-T2D-2026
ELSAYED-T2D-2026
ADA-2026-MEDICINES-CHECKED

keep.3

DIRECT-2018
LEAN-T2D-2026
TAYLOR-T2D-2026
REMISSION-CONSENSUS-CHECKED

keep.4

ADA-STANDARDS
GERSTEIN-T2D-2026

deep.0

DPP-2002
KNOWLER-T2D-2026
NATHAN-T2D-2026
DPP-2002-CHECKED

deep.1

UKPDS-33
HOLMAN-T2D-2026
UKPDS-33-CHECKED
ADA-2026-CARDIO-CHECKED

deep.2

DIRECT-2018
LEAN-T2D-2026
TAYLOR-T2D-2026
DIRECT-2018-CHECKED

deep.3

LOOK-AHEAD-2013
WEXLER-T2D-2026
PETERS-T2D-2026
LOOK-AHEAD-CHECKED

deep.4

ADA-STANDARDS
ELSAYED-T2D-2026
GABBAY-T2D-2026
ADA-2026-MEDICINES-CHECKED

deep.5

ROSENSTOCK-T2D-2026
SATTAR-T2D-2026
ADA-STANDARDS
ADA-2026-MEDICINES-CHECKED
ADA-2026-CARDIO-CHECKED

deep.6

ADA-STANDARDS
KHUNTI-T2D-2026
NIDDK-HYPO-CHECKED

deep.7

ADA-STANDARDS
UKPDS-33
NIDDK-KIDNEY-CHECKED
NIDDK-EYE-CHECKED
NIDDK-FOOT-CHECKED

deep.8

NIDDK-T2D
ADA-STANDARDS
DPPOS-2025-CHECKED
DPPOS-2015-CHECKED

claims.0

ADA-STANDARDS
CDC-T2D
NIDDK-DIAGNOSIS-CHECKED

claims.1

DPP-2002
KNOWLER-T2D-2026

claims.2

DIRECT-2018
NIDDK-T2D

claims.3

LOOK-AHEAD-2013
WEXLER-T2D-2026

claims.4

ADA-STANDARDS
INZUCCHI-T2D-2026

claims.5

DIRECT-2018
LEAN-T2D-2026
DIRECT-2018-CHECKED
REMISSION-CONSENSUS-CHECKED

claims.6

ADA-STANDARDS
UKPDS-33
NIDDK-KIDNEY-CHECKED
NIDDK-EYE-CHECKED
NIDDK-FOOT-CHECKED

source Situation Keys

situations.name-tests
situations.prevention
situations.daily-care
situations.complications

professional Source Ids

BUSE-T2D-2026
INZUCCHI-T2D-2026
DAVIES-T2D-2026
GERSTEIN-T2D-2026
TAYLOR-T2D-2026
LEAN-T2D-2026
KNOWLER-T2D-2026
NATHAN-T2D-2026
ROSENSTOCK-T2D-2026
PETERS-T2D-2026
ELSAYED-T2D-2026
GABBAY-T2D-2026
KHUNTI-T2D-2026
SATTAR-T2D-2026
WEXLER-T2D-2026
HOLMAN-T2D-2026

house Pointers

href
/self/
label
STUDself. For everyday food and movement habits, see STUDself.

positive Guidance

status: DONE
reviewed At: 2026-09-18
professional Count: 15
scope: content-and-positive-titles-only

learn Article

article

format version

presentation

complete-card

overview

sections

id
understanding-type-two
role
explanation
title
What type 2 diabetes means
intro
Understanding how insulin and glucose work helps you distinguish a question about diagnosis from one about prevention or treatment.
items
- label
  Get the right tests when a number or symptom raises a question
  text
  Perhaps a routine blood test came back high, or thirst, frequent urination or blurred vision has made you wonder about diabetes. Glucose is sugar circulating in the blood; insulin is a hormone made by the pancreas that helps the body use and manage it. NIDDK explains that type 2 diabetes combines insulin resistance, meaning cells respond less well to insulin, with an insulin supply that cannot meet the body's needs. Symptoms may develop slowly or be absent. A clinician uses laboratory tests and the history to establish the diagnosis and distinguish type 2 from other forms, including adult-onset type 1. Bring the actual result rather than trying to settle the question with an online symptom list.
  source ids
  niddk-mechanism
  ada-diagnosis-2026
- label
  Use a prediabetes result as a reason to discuss prevention
  text
  If you were told that your glucose is 'borderline,' ask which test and range that describes. Prediabetes means glucose is above the usual range but below the diabetes threshold; it signals increased future risk, rather than an inevitable next stage. William Knowler and the Diabetes Prevention Program researchers tested supported lifestyle change and metformin in adults already at high risk and found that both reduced new diabetes during the trial. That finding gives a reason to ask about a structured prevention service. It does not mean everyone with a mildly elevated A1C has the same risk or needs the same treatment. The useful question is what your result, other risks and available support mean together.
  source ids
  niddk-tests
  dpp-2002
  ada-diagnosis-2026
- label
  Build a care plan around the goals that matter to you
  text
  A new diagnosis can sound like a demand to change everything at once. The ADA's 2026 Standards instead organize care around individual glucose and weight goals, other health conditions, safety, preferences and access. Eating patterns, movement, medicines and follow-up each have a role; a diabetes educator or registered dietitian can help turn the plan into something usable. Two people with the same A1C may need different medicines because one also has heart failure or kidney disease. Ask what each part is intended to accomplish and which problem deserves attention first. Trouble paying for a medicine or fitting meals around shifts is information the care team needs to make the plan work.
  source ids
  ada-medicines-2026
  niddk-living
  lipska-cost
- label
  Keep routine screening and immediate safety in the same plan
  text
  Feeling well after diagnosis is welcome, but it cannot tell you whether every organ is protected. NIDDK explains that early kidney and retinal damage can be silent, while nerve damage can make a foot injury difficult to feel. These are reasons for scheduled checks, not predictions that you will develop every complication. Treatment adds another question: insulin and some insulin-releasing medicines can cause hypoglycemia, meaning blood glucose drops too low. The plan therefore needs both long-term screening and clear instructions for recognizing and responding to a low. Ask when your eyes, kidneys and feet will be checked and whether your medicines require a low-glucose response plan.
  source ids
  niddk-kidneys
  niddk-eyes
  niddk-feet
  niddk-low
id
reading-the-tests
role
explanation
title
How to read A1C and glucose results
items
- label
  Keep the test name, units and timing beside the number
  text
  A1C, also called HbA1c, measures glucose attached to hemoglobin in red blood cells and reflects roughly the preceding three months, with more influence from recent glucose levels. It is reported as a percentage and does not require fasting. Fasting plasma glucose is a laboratory snapshot after at least eight hours without calories. An oral glucose-tolerance test measures the response two hours after a standardized glucose drink. These tests examine different aspects of glucose regulation, so they do not always agree. NIDDK and the ADA distinguish diagnosis from home monitoring: a meter reading can be useful in an established care plan, but an over-the-counter meter or sensor does not complete the diagnostic process.
  source ids
  ada-diagnosis-2026
  niddk-tests
- label
  Use diagnostic thresholds as questions for your clinician
  text
  For nonpregnant adults, ADA diagnostic criteria include A1C of at least 6.5%, fasting plasma glucose of at least 126 mg/dL (7.0 mmol/L), or two-hour plasma glucose of at least 200 mg/dL (11.1 mmol/L) during a 75-gram glucose-tolerance test. Random plasma glucose of at least 200 mg/dL with classic high-glucose symptoms or a hyperglycemic crisis is another route. U.S. prediabetes ranges include A1C 5.7–6.4%, fasting glucose 100–125 mg/dL and two-hour glucose 140–199 mg/dL. Those are diagnostic categories, not a personal treatment target. Pregnancy uses a separate assessment pathway. Save the report so a clinician can interpret the correct test rather than a number remembered without its context.
  source ids
  ada-diagnosis-2026
  niddk-tests
- label
  Resolve confirmation and conflicting results before drawing conclusions
  text
  The ADA requires confirmation when the presentation is not unequivocal: two abnormal results may come from different tests collected together or from testing at different times. A repeat visit is therefore not always necessary, and one normal test does not automatically cancel another repeatedly abnormal test. If A1C and measured glucose disagree, the team should investigate the reason. Pregnancy, some hemoglobin variants, anemia and conditions affecting red blood cell turnover can make A1C misleading; plasma-glucose criteria may be needed. Ask which result establishes the diagnosis, whether confirmation is complete and how the type was determined. Age or body size alone should not decide that every adult has type 2 diabetes.
  source ids
  ada-diagnosis-2026
id
what-prevention-and-treatment-found
role
findings
title
What the major studies actually found
intro
Prevention, remission, glucose control and fewer cardiovascular events are different outcomes. Each study answers its own question.
items
- label
  Supported prevention reduced new diabetes in high-risk adults
  text
  Knowler and the DPP Research Group randomized 3,234 adults without diabetes but with elevated fasting glucose and high glucose after a standardized glucose drink to intensive lifestyle support, metformin or placebo. The lifestyle program included coaching and trial goals of at least 7% weight loss and 150 minutes of activity each week; these describe the intervention, not a personal prescription. Over an average 2.8 years, diabetes incidence was 4.8, 7.8 and 11.0 cases per 100 person-years in the lifestyle, metformin and placebo groups. A person-year is one person's year of observation. The familiar 58% and 31% reductions are relative reductions in incidence versus placebo, not percentage points subtracted from everyone's risk. The result supports organized prevention, with follow-up and support, rather than a detox or an unsupported promise to try harder.
  source ids
  dpp-2002
  niddk-dpp
- label
  More diabetes-free time is a meaningful prevention outcome
  text
  The 2025 DPP follow-up analyzed 3,195 original participants across a period extending to 21 years. Compared with original placebo assignment, mean diabetes-free survival was approximately two years longer with lifestyle assignment and 1.2 years longer with metformin; median differences were 3.5 and 2.5 years. Mean and median summarize the data differently and should not be interchanged. Individual observation periods varied considerably, and all groups were offered lifestyle sessions after the original trial, so this was not twenty-one years of unchanged, separate treatments. Much of the long-term separation came from early benefit. Read the finding as evidence that prevention can delay diabetes and reduce cumulative incidence, even though many people eventually develop it.
  source ids
  dppos-2025
- label
  Glucose control protects small vessels while treatment safety still matters
  text
  UKPDS 33 randomized 3,867 adults with newly diagnosed type 2 diabetes to intensive glucose treatment with insulin or a sulfonylurea, an insulin-releasing medicine, or a conventional policy. Over about ten years, intensive treatment reduced microvascular endpoints by 25% relative to conventional treatment, including eye disease requiring retinal treatment. Microvascular means involving small blood vessels; this evidence is different from proving fewer heart attacks or strokes. Intensive treatment also produced more hypoglycemia and weight gain. Rury Holman's UKPDS work helps explain why sustained glucose management matters, but the study used an earlier treatment era. Its practical lesson is to pursue glucose control with attention to adverse effects, while managing blood pressure, cholesterol and organ risks alongside it.
  source ids
  ukpds-33
  ada-medicines-2026
  ada-kidney-2026
- label
  Supervised weight management achieved remission in a selected group
  text
  Michael Lean, Roy Taylor and colleagues conducted DiRECT across 49 primary-care practices in Scotland and England. Participants were aged 20–65, had diabetes for less than six years, had BMI 27–45 and were not using insulin. The intervention combined temporary formula-diet replacement, gradual food reintroduction, maintenance support and supervised changes to diabetes and blood-pressure medicines. At one year, 46% of the intervention group and 4% of controls met the trial's remission definition: A1C below 6.5% after at least two months off diabetes medicines. That is a substantial result for that program and population. It does not establish that an unsupervised restrictive diet, a juice cleanse or any one supplement reproduces the benefit or is safe.
  source ids
  direct-2018
- label
  Remission includes monitoring and help with maintenance
  text
  The later international consensus led by Matthew Riddle uses remission for A1C below 6.5% measured at least three months after stopping glucose-lowering medicines. This differs from DiRECT's original two-month trial criterion. A good A1C while taking treatment can be excellent control without meeting that definition; stopping a beneficial medicine just to obtain a label is not a goal for this reading companion. Glucose can rise again, and ongoing observation and complication screening remain important. The University of Glasgow's report of the five-year DiRECT extension describes sustained remission in some participants and substantial difficulty maintaining weight loss. The extension followed a remaining subgroup and cannot be read as a repeat of the original randomized one-year result. Remission is a possible clinical outcome, not a promise of a permanent cure.
  source ids
  remission-consensus
  direct-five-year-official
- label
  Value lifestyle benefits and check heart-event evidence separately
  text
  Look AHEAD randomized 5,145 adults with overweight or obesity and type 2 diabetes to intensive lifestyle treatment or diabetes support and education. After a median 9.6 years, the intensive group had lost more weight and had better early A1C and fitness measures, but the primary cardiovascular outcome was not significantly reduced. Event rates were 1.83 versus 1.92 per 100 person-years; the hazard ratio was 0.95, with a confidence interval of 0.83–1.09. That interval includes no difference. The trial measured cardiovascular death, nonfatal heart attack or stroke, or hospitalization for angina. It neither makes lifestyle pointless nor proves that every activity program has the same result. It shows why care should retain lifestyle benefits and use direct outcome evidence for claims about heart protection.
  source ids
  look-ahead
- label
  Read a medicine's benefit by the event and population studied
  text
  A lower A1C, fewer heart-failure admissions and slower kidney decline are separate outcomes. The ADA's 2026 Standards recommend agents with demonstrated benefit for relevant heart and kidney conditions, sometimes irrespective of A1C. SGLT2 inhibitors reduce glucose reabsorption in the kidney; GLP-1 receptor agonists act on a hormone pathway involved in insulin release, appetite and digestion. These class names describe how drugs work, not identical evidence for every member. For heart failure, kidney disease or atherosclerotic disease, meaning disease involving plaque buildup in arteries, the specific drug, population and measured event matter. Ask which benefit supports the proposed medicine and how it will be monitored. Weight loss or a striking glucose response alone cannot establish that every product also prevents every cardiovascular or kidney outcome.
  source ids
  ada-medicines-2026
  ada-kidney-2026
id
making-care-usable
role
application
title
Make daily care understandable and usable
items
- label
  Choose eating support that fits your life and your treatment
  text
  Carbohydrate includes sugars, starches and fiber, and it influences glucose after meals. That does not make every carbohydrate-containing food interchangeable or establish a single correct diet. Alison Evert and the ADA nutrition consensus authors describe individualized eating patterns rather than one ideal carbohydrate, fat and protein ratio. Food quality, quantity, culture, preferences, affordability and the ability to maintain the pattern all matter. Medical nutrition therapy means individualized assessment and counseling from a registered dietitian; it is more than handing someone a forbidden-food list. Discuss major changes, particularly fasting or sharply reducing carbohydrate, before making them when medicines can cause lows. The useful goal is an eating plan the care team can help you understand and safely sustain. Imagine a person whose meal plan assumes a lunch break at noon, while their shift sometimes delays the break. They tell the dietitian what food is actually available and the prescribing clinician when meals are missed or delayed. The useful question is how the eating arrangement and treatment can work together safely, rather than which food to blame for every difficult reading. At follow-up, they can report whether the agreed arrangement was possible and what still prevented it. If access to food or breaks remains unreliable, that is part of the care problem, not evidence that the person needs a stricter list. This invented situation does not specify a meal or medicine change. It demonstrates why cultural fit, affordability, work conditions and medicines belong in one individualized discussion, especially when treatment can cause low glucose.
  source ids
  nutrition-consensus
  ada-easd-2022
  niddk-living
- label
  Make movement part of care with an appropriate safety plan
  text
  NIDDK describes regular activity as helpful for glucose, fitness, blood pressure and well-being. For someone who sits for much of a shift, the first practical issue may be finding a feasible activity rather than copying an athlete's routine. Existing foot problems, heart symptoms, functional limitations or medicines that cause lows may change what is appropriate and what monitoring is needed. Ask the care team how movement fits your health and treatment, and seek support for barriers. Ordinary food and movement habits are also discussed in STUDself; the related Learn topics on fitness, nutrition and sleep offer further named-source teaching. Those connections complement diabetes care rather than deciding a treatment plan.
  source ids
  niddk-living
  niddk-low
  niddk-feet
- label
  Know why each medicine is in the plan
  text
  The 2026 ADA Standards make effectiveness, heart and kidney conditions, weight, hypoglycemia, tolerability, cost and preferences part of medication choice. Metformin remains useful for many people and may be chosen for effectiveness, affordability and tolerance. An SGLT2 inhibitor or GLP-1 medicine may be considered for a different or additional goal, and insulin can be appropriate when insulin supply is insufficient or glucose is severely elevated. Ask what benefit is expected, which adverse effects to report and when the plan will be reviewed. Different choices can both be reasonable. Raise supply or cost problems promptly rather than quietly rationing a treatment; Kasia Lipska's public insulin-cost work shows why affordability belongs inside the clinical conversation.
  source ids
  ada-medicines-2026
  lipska-cost
- label
  Use screening results to protect organs before symptoms appear
  text
  Kidney checks combine urine albumin, a protein that may leak when kidneys are damaged, with a blood test estimating filtration, often called eGFR. They answer different questions and are not replaced by a normal A1C. NIDDK recommends yearly kidney testing for people with type 2 diabetes. A retinal examination checks the back of the eye for changes that clear everyday vision can miss. A foot assessment checks skin, circulation and sensation, since reduced feeling can hide a blister or wound. Keep the results and next review dates together, and have your clinicians set the appropriate eye and foot schedule. New wounds, sudden vision changes or other new symptoms deserve attention between routine appointments.
  source ids
  niddk-kidneys
  niddk-eyes
  niddk-feet
- label
  Keep a short record of the pattern and the barriers
  text
  A useful follow-up record contains the latest lab report, home readings if your team asked you to collect them, symptoms, medicine changes and questions about access or daily routines. Record the test's units and timing; otherwise a fasting result and an after-meal reading can look like conflicting answers to the same question. Note missed meals, unexpected lows or side effects without treating the record as a character score. Monica Peek's diabetes work emphasizes informed shared decisions, and the Behavioral Diabetes Institute identifies practical and emotional barriers as part of care. Bring one obstacle you want help solving. A record is useful when it improves the conversation, not when it creates an exhausting obligation to track everything.
  source ids
  niddk-tests
  ada-medicines-2026
  peek-profile
  bdi-resources
id
where-the-field-differs
role
perspectives
title
Where treatment choices and evidence differ
intro
These are real questions about fit, outcomes and durability. They do not turn every option into equally strong evidence.
items
- label
  Discuss treatment sequence in light of heart, kidney and access needs
  text
  The older 'metformin first for everyone' shorthand conflicts with a more condition-specific approach. The ADA/EASD consensus and 2026 ADA Standards give therapies with demonstrated organ benefits a role that need not wait for metformin to fail in people with relevant heart or kidney disease. Metformin may still be a sensible starting choice when those indications are absent and it fits the person's circumstances. The practical debate concerns sequence, combination, cost, adverse effects and priorities; it is not a contest between being pro-medicine or pro-lifestyle. A history of stroke, heart failure and chronic kidney disease are also distinct clinical problems, not one interchangeable indication for every newer drug. Ask which condition is driving the choice.
  source ids
  ada-medicines-2026
  ada-easd-2022
- label
  Compare eating patterns by sustained benefit and safety
  text
  Clinicians and researchers differ over how much to emphasize carbohydrate reduction versus other ways to improve diet quality and achieve weight goals. The ADA/EASD consensus reports short-term glucose benefits from lower-carbohydrate approaches, while noting that their comparative advantage is less evident with longer follow-up. It also recognizes Mediterranean and other individualized patterns. This is a disagreement about the best sustainable route for particular people, not evidence that one named diet is mandatory or that carbohydrate has no effect on glucose. Definitions of 'low carbohydrate' also differ across studies. Compare duration, actual adherence, medicine changes and outcomes before borrowing a headline, and discuss low-glucose safety when changing eating patterns.
  source ids
  ada-easd-2022
  nutrition-consensus
- label
  Match glucose targets to benefit, burden and the person
  text
  UKPDS supports long-term glucose management in newly diagnosed adults. ACCORD asked a different question in 10,251 generally older adults with established cardiovascular disease or additional cardiovascular risks: would an intensive strategy targeting A1C below 6.0% reduce major cardiovascular events compared with a standard strategy? The intensive arm was stopped after about 3.5 years because mortality was higher; severe hypoglycemia and major weight gain were also more frequent. That does not identify the harmful mechanism or prove that naturally having a low A1C is dangerous. It challenges the assumption that rapidly pursuing a near-normal number with an intensive treatment strategy helps everyone. The clinician and patient weigh the target, treatment burden and safety together.
  source ids
  ukpds-33
  accord-2008
  ada-medicines-2026
- label
  Evaluate remission approaches with eligibility and maintenance attached
  text
  The possibility of remission is established; how to make it accessible and durable for different people remains an active clinical question. DiRECT studied a particular supported weight-management program in people with relatively recent diabetes who were not using insulin. Its result cannot settle comparisons with every other dietary approach, medication strategy or metabolic operation. Taylor's work on liver and pancreas fat offers a mechanism for improvement in some people, but explaining a mechanism is not predicting an individual's chance of remission. Ask whether a proposed service has relevant evidence, clinical supervision and a maintenance plan. Continuing effective treatment or resuming it when glucose rises is a health decision, not failure to win a remission label.
  source ids
  direct-2018
  direct-five-year-official
  remission-consensus
  taylor-profile
  ada-medicines-2026
id
checking-common-claims
role
findings
title
Check common diabetes claims
intro
Established means the claim is supported within the stated limits. Not means the claim overreaches the evidence. Talk means a popular saying should not guide care.
items
- label
  Use laboratory testing and the clinical history together
  text
  Claim: 'Type 2 diabetes is named with blood tests such as A1C and fasting glucose.' Verdict: established, with a distinction. These tests can establish diabetes, with confirmation when needed; history and sometimes additional testing identify the type. A tired afternoon or a high home reading is a reason to seek assessment, not a completed diagnosis. Knowing which question the test answers prevents an adult with another diabetes type from being assumed to have type 2.
  source ids
  ada-diagnosis-2026
  niddk-tests
- label
  Ask about supported prevention when glucose is elevated
  text
  Claim: 'A structured lifestyle program can reduce new diabetes in high-risk adults.' Verdict: established. DPP compared an intensive supported intervention with placebo and metformin, rather than simply comparing people who intended to be healthy with those who did not. Its percentage reductions describe incidence in the groups studied. A prevention service should be judged by the support it delivers and whom it serves, not by a trial statistic used as an individual guarantee.
  source ids
  dpp-2002
  niddk-dpp
- label
  Require evidence before trusting a universal reversal promise
  text
  Claim: 'A supplement can reverse type 2 diabetes for everyone.' Verdict: not. NCCIH describes limited and inconsistent evidence for supplements, including small studies with differing products and outcomes; possible glucose effects do not establish universal remission or a cure. Supplements can interact with medicines or have adverse effects. DiRECT's remission result came from a supervised clinical program, not a bottled product. Bring supplement questions to the care team and do not replace effective diabetes treatment with a marketing claim.
  source ids
  nccih-supplements
  direct-2018
- label
  Keep lifestyle benefits tied to the outcomes actually shown
  text
  Claim: 'Intensive lifestyle always prevents heart attacks in type 2 diabetes.' Verdict: not. Look AHEAD did not significantly reduce its primary cardiovascular outcome compared with diabetes support and education despite improvements in weight and other measures. Better fitness or glucose is useful without proving the claim about heart events. Retain lifestyle care and discuss blood pressure, cholesterol and medicines with demonstrated benefits where relevant; neither the positive markers nor the negative primary result should be stretched into an all-or-nothing conclusion.
  source ids
  look-ahead
  ada-kidney-2026
- label
  Let individual needs guide the first medicine
  text
  Claim: 'Everyone with type 2 diabetes must start metformin and nothing else.' Verdict: not. Current ADA guidance includes condition-specific heart and kidney protection, glucose and weight goals, and individual safety and access. Metformin remains an important option, but a universal single-drug rule misses those differences. The prescribing decision needs the full health history and a discussion of what the person can obtain and tolerate.
  source ids
  ada-medicines-2026
- label
  Recognize remission as a supported result with a defined meaning
  text
  Claim: 'Some people in a supervised formula-diet trial reached remission.' Verdict: established. DiRECT found 46% versus 4% remission at one year using its original two-month medication-free criterion. The later consensus uses at least three months. Neither definition means a single normal reading proves permanent recovery. Ask which definition and follow-up period a headline uses before comparing results.
  source ids
  direct-2018
  remission-consensus
- label
  Keep screening appointments even when you feel well
  text
  Claim: 'If you feel fine you can skip eye and kidney screening.' Verdict: talk. Early changes may produce no pain or obvious loss of function, so a retinal examination and urine and blood kidney tests provide information that symptoms cannot. Foot checks add sensation, skin and circulation information. Feeling well is useful news, but it cannot stand in for these different assessments.
  source ids
  niddk-eyes
  niddk-kidneys
  niddk-feet
- label
  Treat insulin as help for the body's needs
  text
  A popular saying treats needing insulin as proof that someone failed. That is not a clinical finding. Type 2 diabetes includes inadequate insulin supply relative to need, and ADA guidance includes insulin when the clinical situation warrants it. William Polonsky's Behavioral Diabetes Institute offers education on concerns about insulin and the emotional burden of diabetes. Discuss fear, inconvenience or stigma openly so they can be addressed. A change in treatment reflects a care need, not a judgment about effort or character.
  source ids
  niddk-mechanism
  ada-medicines-2026
  bdi-resources
id
getting-safe-support
role
cautions
title
Know when to get help
items
- label
  Get a low-glucose plan before you need it
  text
  NIDDK describes hypoglycemia as glucose below the healthy range for the person; below 70 mg/dL is a common alert level, but your team should explain your threshold and response. Insulin, sulfonylureas and other insulin-releasing medicines carry particular risk. Missed or delayed meals, alcohol, more activity than usual, illness or changing kidney function can alter that risk. Shakiness, sweating, hunger, confusion or trouble speaking may occur, and some people have little warning. Obtain written instructions for checking and treating a low, when to call for help, and whether rescue glucagon is needed. Someone close to you should know the emergency plan if you cannot treat yourself. Repeated lows deserve a prompt treatment review rather than acceptance as the price of good control.
  source ids
  niddk-low
  ada-medicines-2026
- label
  Seek urgent care for severe symptoms and use your illness plan
  text
  Severe vomiting with inability to keep fluids down, trouble breathing, severe confusion or loss of consciousness needs urgent medical help. Chest pain also needs urgent assessment. CDC explains that diabetic ketoacidosis, an emergency caused by insufficient insulin and accumulating acids called ketones, can occur in type 2 as well as type 1 diabetes. The ADA also notes that SGLT2-associated ketoacidosis can occur without the very high glucose someone might expect. Ask the care team for illness and procedure instructions specific to your medicines before an illness or operation. Do not improvise medicine changes from this article, and do not wait for a reassuring A1C or sensor number when severe symptoms are present.
  source ids
  cdc-dka
  niddk-mechanism
  niddk-low
  ada-medicines-2026
- label
  Use this reading to prepare for qualified care
  text
  This is a reading companion, not a diagnosis, diet prescription, or medicine list. High glucose, thirst, unexplained weight change, or known diabetes belong with a qualified clinician. Do not start, stop, or change medicines from this text. Severe vomiting, confusion, or chest pain needs urgent care. This page does not treat one person or promise reversal. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.
  source ids
  niddk-tests
  ada-medicines-2026
  cdc-dka
id
one-useful-next-step
role
next_steps
title
Prepare one useful care conversation
items
- label
  Bring your glucose results and main question to your clinician
  text
  Make a short visit note with your latest A1C or laboratory glucose result, its date and units, any symptoms, your current medicines and supplements, and the first question you want answered. A useful question might be whether confirmation is complete, whether a prevention service fits, or what a treatment is protecting. If you already have diabetes, include relevant eye, kidney and foot check dates. Bring home readings only as part of the monitoring plan you have been given. The purpose is to connect the evidence to a qualified assessment of your circumstances, not to use a page as a diagnosis or select a medicine yourself.
  source ids
  niddk-tests
  ada-medicines-2026
  niddk-kidneys
  niddk-eyes
  niddk-feet
- label
  Try asking which support matches your current stage
  text
  With prediabetes, ask whether a recognized prevention program is appropriate and what coaching and follow-up it offers. With established diabetes, ask how food, activity, medicines and diabetes education will work together. Name one practical obstacle, such as shift work, food access or cost, so the discussion can include it. DPP supports structured prevention in high-risk adults; diabetes self-management education helps make established care understandable. These are different services for different jobs, not interchangeable challenges with the same promised outcome.
  source ids
  niddk-dpp
  ada-easd-2022
  niddk-living
- label
  Try confirming the next checks and the safety instructions
  text
  Before the visit ends, ask when the next glucose review, eye assessment, kidney tests and foot assessment are due. If your medicines can cause low glucose, ask the clinician or educator to explain the recognition, response and emergency plan in words you can repeat back. Ask whom to contact about repeated lows, illness, side effects or difficulty obtaining treatment. A written next step and contact point make the plan easier to keep when life changes. The treating team sets the timing and treatment; your preparation helps identify gaps and unanswered questions.
  source ids
  niddk-low
  niddk-kidneys
  niddk-eyes
  niddk-feet
  ada-medicines-2026

related

nutrition
fitness
sleep

sources

id
niddk-mechanism
title
Symptoms & Causes of Diabetes
url
https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes
kind
official
accessed at
2026-10-01
supports
Insulin resistance plus insufficient insulin supply, slow or absent type 2 symptoms, adult type 1 and possible ketoacidosis.
limitations
Public education, not individual diagnosis or a comprehensive account of every cause.
id
niddk-tests
title
Diabetes Tests & Diagnosis
url
https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis
kind
official
accessed at
2026-10-01
supports
Test meanings, nonpregnant diagnostic and prediabetes ranges, confirmation, home-meter limitation and classification.
limitations
Page last reviewed July 2022; current diagnostic details were cross-checked against ADA 2026.
id
ada-diagnosis-2026
title
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC12690183/
kind
guideline
accessed at
2026-10-01
supports
Tables 2.1 and 2.2; confirming diagnosis with two abnormal results together or separately; discordant tests; A1C interference; type classification; prevention evidence largely from impaired-glucose-tolerance populations.
limitations
Professional guidance; relevant full-text sections informed this article. It is not an individual assessment.
id
dpp-2002
title
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
url
https://pubmed.ncbi.nlm.nih.gov/11832527/
kind
study
accessed at
2026-10-01
supports
3,234 high-risk adults; trial goals; mean 2.8 years; incidence 4.8/7.8/11.0 per 100 person-years; 58%/31% relative reductions.
limitations
This account relies on the primary abstract; the full paper was not reviewed. Participants had elevated fasting and post-load glucose, so the findings do not cover every presentation of prediabetes based on A1C alone.
id
niddk-dpp
title
Diabetes Prevention Program (DPP)
url
https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp
kind
official
accessed at
2026-10-01
supports
NIH trial overview, supported prevention, original intervention and follow-up context.
limitations
Official study translation, not a guarantee for an individual or proof that all commercial programs reproduce DPP.
id
dppos-2025
title
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial
url
https://pubmed.ncbi.nlm.nih.gov/40311647/
kind
study
accessed at
2026-10-01
supports
3,195 participants; varying observation periods; group crossover to lifestyle support; mean and median diabetes-free-survival gains distinguished.
limitations
This account relies on the primary abstract; the full paper was not reviewed. It follows original assignments after interventions changed, rather than comparing unchanged treatments for 21 years.
id
ukpds-33
title
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
url
https://pubmed.ncbi.nlm.nih.gov/9742976/
kind
study
accessed at
2026-10-01
supports
3,867 newly diagnosed adults; approximately ten years; 25% relative reduction in microvascular endpoints; more hypoglycemia and weight gain.
limitations
The available primary abstract was truncated at the end; the full paper was not reviewed. The earlier treatment era and population limit its use for choosing modern medicines.
id
direct-2018
title
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
url
https://pubmed.ncbi.nlm.nih.gov/29221645/
kind
study
accessed at
2026-10-01
supports
49 practices; eligibility; supported intervention components; 46% versus 4% remission at one year; original two-month medicine-free criterion.
limitations
Opened primary PubMed abstract, not full text. Selected population, open-label design, supervised medicine changes; no home diet instructions or universal remission probability.
id
remission-consensus
title
Consensus report: definition and interpretation of remission in type 2 diabetes
url
https://pubmed.ncbi.nlm.nih.gov/34458934/
kind
guideline
accessed at
2026-10-01
supports
Remission terminology; usual A1C <6.5% criterion measured at least three months after glucose-lowering treatment cessation; active observation.
limitations
Opened consensus abstract; formal terminology does not establish permanent cure or mandate stopping treatment. Ongoing screening also supported by relevant NIDDK pages.
id
direct-five-year-official
title
Diet intervention links longer remissions of type 2 diabetes and improved health
url
https://www.gla.ac.uk/news/archiveofnews/2024/february/headline_1049216_en.html
kind
official
accessed at
2026-10-01
supports
University report of observational DiRECT extension, remaining participants, maintenance support, weight regain and continuing remission in some people.
limitations
Official investigator-institution report of the 2024 extension, not independently read full trial paper. Article deliberately avoids hospital-event claims, causal interpretations and treating the remaining subgroup as the entire original cohort.
id
look-ahead
title
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
url
https://pubmed.ncbi.nlm.nih.gov/23796131/
kind
study
accessed at
2026-10-01
supports
5,145 adults; median 9.6 years; weight/A1C/fitness improvement; primary event definition; event rates, hazard ratio and confidence interval.
limitations
This account relies on the primary abstract; the full paper was not reviewed. The primary cardiovascular result does not establish that lifestyle care has no benefits.
id
ada-medicines-2026
title
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/
kind
guideline
accessed at
2026-10-01
supports
Recommendations 9.5–9.23 and Table 9.2: individualized treatment; cardiovascular/kidney benefits irrespective of A1C where indicated; agent-specific outcomes, safety, cost, insulin role and SGLT2 ketoacidosis warning.
limitations
Relevant full-text sections informed this article. These are professional recommendations, not a dose guide or individual prescription; evidence for specific medicines must remain distinct from claims about entire drug classes.
id
ada-kidney-2026
title
Approach to Managing CKD in Diabetes
url
https://diabetes.org/sites/default/files/2026-04/Management-Of-CKD-in-People-With-Diabetes-HCP-Apr26.pdf
kind
guideline
accessed at
2026-10-01
supports
ADA 2026 professional infographic connects glucose, blood pressure, cardiovascular care and therapies with demonstrated kidney benefits.
limitations
One-page professional summary opened; specific thresholds and prescribing sequences remain outside this article's guidance.
id
accord-2008
title
Effects of intensive glucose lowering in type 2 diabetes
url
https://pubmed.ncbi.nlm.nih.gov/18539917/
kind
study
accessed at
2026-10-01
supports
10,251 high-risk adults; intensive A1C target <6.0%; mortality-driven early stop at 3.5 years; more assisted hypoglycemia and major weight gain.
limitations
This account relies on the primary abstract. The intensive strategy does not isolate a mechanism of harm or show that every low A1C is dangerous.
id
ada-easd-2022
title
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC10008140/
kind
guideline
accessed at
2026-10-01
supports
Nutrition therapy; different eating patterns; short-term versus longer-term carbohydrate findings; fasting and medication safety; diabetes education and organ-protection framework.
limitations
Relevant sections of the 2022 consensus informed this article; ADA 2026 supplies the newer medication guidance.
id
nutrition-consensus
title
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7011201/
kind
guideline
accessed at
2026-10-01
supports
Evert-led consensus, individualized macronutrient mix, carbohydrate quality, definitions varying by approach and registered-dietitian nutrition therapy.
limitations
Relevant full-text sections of the 2019 consensus explain concepts consistent with later ADA/EASD guidance; they are not a personalized diet prescription.
id
niddk-living
title
Healthy Living with Diabetes
url
https://www.niddk.nih.gov/health-information/diabetes/overview/healthy-living-with-diabetes
kind
official
accessed at
2026-10-01
supports
Meal patterns, movement, sleep, registered-dietitian support, gradual changes and individualized daily-care discussion.
limitations
Public education; no individual exercise clearance, restrictive diet, calorie target or supplement regimen inferred.
id
niddk-low
title
Low Blood Glucose (Hypoglycemia)
url
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia
kind
official
accessed at
2026-10-01
supports
Common alert level; insulin/insulin-releasing medicines; symptoms, absent warnings, meals/activity/alcohol/illness and recognition/response planning including rescue glucagon.
limitations
Official education. Individual response instructions must come from treating team; the article does not replace emergency care.
id
niddk-kidneys
title
Diabetic Kidney Disease
url
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease
kind
official
accessed at
2026-10-01
supports
Asymptomatic early disease; urine albumin and blood filtration tests; yearly testing in type 2 diabetes.
limitations
General education; personal monitoring and treatment depend on results and other conditions.
id
niddk-eyes
title
Diabetic Eye Disease
url
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-eye-disease
kind
official
accessed at
2026-10-01
supports
Early retinal disease may have no pain or vision change; dilated examination and prompt review of sudden vision changes.
limitations
Eye-care schedule and treatment require assessment; feeling well does not establish absence of damage.
id
niddk-feet
title
Diabetes & Foot Problems
url
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/foot-problems
kind
official
accessed at
2026-10-01
supports
Loss of sensation, circulation and hidden injuries; foot assessment and symptoms between visits.
limitations
General foot-care education, not wound treatment or an individual examination.
id
cdc-dka
title
Diabetic Ketoacidosis
url
https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html
kind
official
accessed at
2026-10-01
supports
DKA can occur in type 2; ketone mechanism; urgent help for vomiting/inability to keep fluids, breathing trouble and severe illness.
limitations
Official emergency education. The article does not supply insulin adjustments or replace an individualized sick-day plan.
id
nccih-supplements
title
Diabetes and Dietary Supplements: What You Need To Know
url
https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements-what-you-need-to-know
kind
official
accessed at
2026-10-01
supports
Weak/inconsistent supplement evidence, heterogeneous trials, possible interactions and harms, no replacement for proven treatment or universal cure claim.
limitations
Official evidence summary; possible effects on particular markers are not remission or outcome evidence. Older prevalence/age statistics on this page are not adopted.
id
lipska-cost
title
The Price of Insulin: A Q&A with Kasia Lipska
url
https://medicine.yale.edu/news-article/the-price-of-insulin-a-qanda-with-kasia-lipska/
kind
professional
accessed at
2026-10-01
supports
Public explanation of insulin affordability as a barrier that should be discussed with the care team.
limitations
Historical interview and research setting, not a current price list, current insurance policy or nationwide prevalence estimate.
id
peek-profile
title
Monica Peek, MD, MPH — UChicago Medicine
url
https://www.uchicagomedicine.org/find-a-physician/physician/monica-peek
kind
professional
accessed at
2026-10-01
supports
Verified internal-medicine role, diabetes disparities research, community education and informed shared decision-making.
limitations
Professional profile provides practice context and credentials, not independent efficacy evidence for a treatment.
id
bdi-resources
title
Healthcare Professionals Resources — Behavioral Diabetes Institute
url
https://behavioraldiabetes.org/for-healthcare/
kind
professional
accessed at
2026-10-01
supports
Named Polonsky education addressing diabetes distress, medication barriers, insulin concerns, hypoglycemia worry and environmental barriers.
limitations
Resource descriptions opened; linked training videos not watched. Practical professional perspective does not establish clinical-event effects.
id
taylor-profile
title
Professor Roy Taylor — Newcastle Magnetic Resonance Centre
url
https://www.ncl.ac.uk/magres/staff/profile/roytaylor.html
kind
professional
accessed at
2026-10-01
supports
Verified emeritus role, mechanism/remission research, retinal-screening contribution and public-information link.
limitations
Researcher's account of mechanism and contribution; article deliberately does not adopt his profile's broad causal language as a universal prediction.
id
remission-question-signal
title
r/diabetes_t2: remission — question about weight loss versus carbohydrate restriction
url
https://www.reddit.com/r/diabetes_t2/comments/vp3xs2/remission/
kind
question_signal
accessed at
2026-10-01
supports
Opened reader question motivated clear separation of calorie/weight change, eating pattern, glucose control and remission.
limitations
Older thread inspected now; self-reports and comments are not verified clinical evidence, current demand measurement or dietary guidance. Not used as factual support for an article item.

professional panel

name
William C. Knowler
credential
MD, DrPH; NIDDK Scientist Emeritus, Phoenix Epidemiology & Clinical Research Branch
official url
https://www.niddk.nih.gov/about-niddk/staff-directory/biography/knowler-william
public usefulness
Official Research in Plain Language explanation makes prevention trials and their uncertainty understandable.
contribution
DPP and DPPOS investigator; grounds the distinction between lower incidence and permanent prevention.
boundary
Group trial results in high-risk adults do not predict every reader's risk.
reviewed at
2026-10-01
name
David M. Nathan
credential
MD; director of the Diabetes Clinical Research Center at Massachusetts General Hospital; Harvard professor of medicine
official url
https://advances.massgeneral.org/contributors/contributor.aspx?id=2478
public usefulness
Mass General's public Advances in Motion profile connects readers to clinical research and education; DPP authorship verified in primary study.
contribution
Clinical trial work helps explain prevention and treatment comparisons without reducing them to slogans.
boundary
Clinical-research leadership is not personal treatment advice or endorsement of a commercial program.
reviewed at
2026-10-01
name
Melanie J. Davies
credential
MBChB, MD; professor of diabetes medicine, University of Leicester; honorary consultant diabetologist
official url
https://le.ac.uk/people/melanie-davies
public usefulness
Public university profile describes self-management, screening and prevention research; ADA/EASD consensus is an accessible professional teaching source.
contribution
Lead author of 2022 consensus; connects nutrition, education and medicines in person-centered care.
boundary
Consensus recommendations are conditional guidance, not proof that every option helps every person.
reviewed at
2026-10-01
name
Kamlesh Khunti
credential
Professor of primary care diabetes and vascular medicine, University of Leicester
official url
https://le.ac.uk/people/kamlesh-khunti
public usefulness
University and Leicester Diabetes Centre public profiles describe primary-care, risk-assessment and ethnic-health work; university page links professional social profile.
contribution
Examines how primary care, coexisting conditions and differences among populations affect the interpretation of diabetes evidence.
boundary
Real-world associations and risk tools are not interchangeable with randomized treatment effects.
reviewed at
2026-10-01
name
Silvio E. Inzucchi
credential
MD; professor of medicine in endocrinology, Yale School of Medicine
official url
https://medicine.yale.edu/profile/silvio-inzucchi/
public usefulness
Official Yale profile provides clinical and teaching background, publications and public links on diabetes care.
contribution
Treatment-consensus and cardiovascular trial work helps distinguish glucose lowering from organ protection.
boundary
Outcome evidence belongs to specific agents and populations; a named clinician cannot substitute for prescribing assessment.
reviewed at
2026-10-01
name
Anne L. Peters
credential
MD; USC professor of medicine and director of USC Clinical Diabetes Programs
official url
https://keck.usc.edu/faculty-search/anne-louise-peters/
public usefulness
Official profile records diabetes books, public programs, exercise media and clinical education.
contribution
Adds practical monitoring, exercise and technology-safety perspective; Look AHEAD involvement is documented on the official profile.
boundary
Public education and device expertise do not establish that every lifestyle intervention prevents heart events.
reviewed at
2026-10-01
name
John B. Buse
credential
MD, PhD; endocrinology-trained physician; UNC diabetes-center director as identified in ADA's 2024 professional award profile
official url
https://professional.diabetes.org/awards/outstanding-physician-clinician-diabetes-award-john-b-buse
public usefulness
ADA's public profile explains clinical/translational work; the ADA/EASD consensus provides accessible professional teaching with his authorship.
contribution
Consensus and clinical trial contribution supports shared treatment choices and careful assessment of safety and efficacy.
boundary
The role is documented in a 2024 professional profile, rather than a current appointment check; it does not supply an individual recommendation.
reviewed at
2026-10-01
name
Michael E. J. Lean
credential
MD; University of Glasgow human-nutrition researcher and consultant physician
official url
https://www.gla.ac.uk/schools/medicine/staff/mikelean/
public usefulness
University's public DiRECT explanations and listed lectures translate remission research for wider audiences.
contribution
DiRECT investigator; keeps formula replacement, reintroduction, supervision and maintenance together.
boundary
Selected trial eligibility and remaining extension participants limit generalization; remission is not universal.
reviewed at
2026-10-01
name
Roy Taylor
credential
MD, FRCP; emeritus professor of medicine and metabolism, Newcastle University
official url
https://www.ncl.ac.uk/magres/staff/profile/roytaylor.html
public usefulness
Official profile links public diabetes-remission information and explains retinal-screening and mechanism work.
contribution
Connects liver/pancreas fat research to DiRECT while distinguishing a mechanism from a personal remission forecast.
boundary
Mechanistic account and investigator interpretation do not prove that all type 2 diabetes shares one reversible cause or endorse products using his name.
reviewed at
2026-10-01
name
Naveed Sattar
credential
Physician, PhD; University of Glasgow professor of cardiometabolic medicine and honorary consultant
official url
https://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/naveedsattar/
public usefulness
Official profile documents international teaching and guideline contributions; public cardiometabolic explanation helps frame glucose beside heart and kidney outcomes.
contribution
DiRECT and cardiovascular/outcome-trial contributions provide a bridge between weight, diabetes and organ risk.
boundary
Research and guideline roles do not make every drug in a class equivalent; industry-funded trial roles require evidence to be judged on design and results.
reviewed at
2026-10-01
name
Hertzel C. Gerstein
credential
Endocrinologist; McMaster professor of medicine; PHRI senior scientist and diabetes-program lead
official url
https://www.phri.ca/research/in-charge/
public usefulness
PHRI's public study and biography pages explain diabetes outcome trials and the importance of measuring events.
contribution
ACCORD and other outcome-trial leadership helps clarify why glucose targets and cardiovascular outcomes require separate evaluation.
boundary
One intensive-strategy trial does not show that every low A1C is unsafe or identify a single cause of mortality.
reviewed at
2026-10-01
name
Deborah J. Wexler
credential
MD, MSc; board-certified endocrinology, diabetes and metabolism physician at Mass General Brigham
official url
https://www.massgeneralbrigham.org/en/doctors/w/deborah-wexler-3004311
public usefulness
Official profile describes clinical-effectiveness research, ADA/EASD consensus authorship and NIDDK Diabetes in America editing.
contribution
Her work emphasizes clinical effectiveness and care that patients can use in daily life, alongside laboratory measures.
boundary
Professional interpretation is not a new trial or proof of a particular treatment for an individual.
reviewed at
2026-10-01
name
Rury R. Holman
credential
Physician; Oxford professor of diabetic medicine and Diabetes Trials Unit emeritus director
official url
https://www2.dtu.ox.ac.uk/staff/ruryholman.php
public usefulness
Official trials-unit profile links manuscripts and conference work and explains UKPDS risk tools used in evidence assessment.
contribution
UKPDS chief investigator; preserves the microvascular outcome and safety tradeoff behind glucose control.
boundary
Historical treatment policy and risk models are not a modern drug menu or an individual complication forecast.
reviewed at
2026-10-01
name
Alison B. Evert
credential
MS, RDN, CDCES, FADCES; registered dietitian nutritionist and diabetes educator
official url
https://medicine.wsu.edu/news/2025/11/03/nep-alum-brings-dietetics-care/
public usefulness
Official WSU profile describes nutrition education, telemedicine and embedding educators in primary care; lead author of accessible ADA nutrition consensus.
contribution
Adds dietitian perspective, individualized eating patterns and the difference between practical support and a forbidden-food list.
boundary
A 2019 consensus and educator profile do not set an individual's diet or establish a mandatory macronutrient ratio.
reviewed at
2026-10-01
name
Kasia J. Lipska
credential
MD, MHS; Yale associate professor of medicine, endocrinologist and clinical investigator
official url
https://medicine.yale.edu/profile/kasia-lipska/
public usefulness
Yale's public insulin-cost Q&A and official research profile explain affordability and severe-hypoglycemia concerns.
contribution
Keeps treatment burden, older-adult safety and access in discussion of glucose targets and medication choice.
boundary
Historical local affordability research is not current national pricing or prevalence; observational harms require careful interpretation.
reviewed at
2026-10-01
name
Monica E. Peek
credential
MD, MPH; UChicago internal-medicine physician and professor; Chicago Center for Diabetes Translational Research associate director
official url
https://www.uchicagomedicine.org/find-a-physician/physician/monica-peek
public usefulness
Official patient-facing video transcript and profile describe community education and shared decisions in diabetes care.
contribution
Brings access, racial/cultural barriers and informed patient participation into the practical follow-up conversation.
boundary
Profile describes professional practice and research interests, not randomized proof for a particular intervention.
reviewed at
2026-10-01
name
William H. Polonsky
credential
PhD; Behavioral Diabetes Institute president; professional diabetes-psychosocial educator
official url
https://www.psadgroup.org/members-directory/159/polonsky-william/
public usefulness
BDI's opened resource page lists his public professional education on diabetes distress, insulin concerns, motivation and medication barriers.
contribution
Supports respectful language about insulin and bringing emotional/practical barriers to the care team.
boundary
Resource descriptions were read, not the linked videos; emotional support does not replace clinical treatment or prove event prevention.
reviewed at
2026-10-01

Download original public profile Download complete article

End of Type 2 diabetes